 
  
 
 Title:  Safety and Feasibility of a Vertebral Body 
Tethering Technique for Pediatric 
Idiopathic Scoliosis  
NCT#:  [STUDY_ID_REMOVED]  
Short Title:  Vertebral Body Tethering Outcomes  
Drug or Device Name(s):  Anterior Vertebral Tether Device  
From the Creo® Stabilization System , 
Transition ™ Stabilization System , and SILC™ 
Fixation System of Globus Medical, Inc.  
FDA IDE:  G170023  
Regulatory Sponsor:  Patrick J. Cahill, MD  
eIRB Number:  17-013694  
Protocol Date:  02/27/2020  
  Amendment 1 Date: 07/18/2017  
Amendment 2 Date: 07/28/2017  
Amendment 3 Date: 11/05/2017  
Amendment 4 Date: 06/29/2018  
Amendment 5 Date: 06/07/2019  
Amendment 6 Date: 07/12/2019  
Amendment 7 Date: 09/23/2019  
Amendment 8 Date: 02/27/2020  
  
   
  
   ii 
 
Title:  Safety and Feasibility of a Vertebral Body Tethering 
Technique  for Pediatric Idiopathic Scoliosis  
Short Title : Vertebral Body Tethering Outcomes  
Drug or Device Name(s):  Anterior Vertebral Tether Device  
From the Creo ® Stabilization System , Transition ™ Stabilization 
System , and SILC™ Fixation System  of Globus Medical, Inc.  
FDA ID E: G170023  
Regulatory Sponsor:  Patrick J . Cahill, MD  
 
eIRB Number : 17-013694  
Protocol Date:  06/29/2018  
Amendment 1 Date: 07/18/2017  
Amendment 2 Date:  07/28/2017  
Amendment 3 Date: 11/05 /2017  
Amendment 4 Date:  06/29/2018  
 Amendment 5 Date: 06/07/2019  
Amendment 6 Date: 07/12/2019  
Amendment 7 Date: 09/23/2019  
Amendment 8 Date: 02/27/2020  
Sponsor and Study Principal Investigator:  
[INVESTIGATOR_109062] J . Cahill, MD  
The Children’s Hospi[INVESTIGATOR_6684]  
[ADDRESS_1213153]  
Philadelphia, PA [ZIP_CODE]  
Phone : ([PHONE_18018]  
Email: [EMAIL_16460]  
 
Study Sub -Investigator:  
John M. Flynn , MD  
The Children’s Hospi[INVESTIGATOR_6684]  
[ADDRESS_1213154]  
Philadelphia, PA [ZIP_CODE]  
   
  
   iii 
Phone : ([PHONE_18019]  
Email: [EMAIL_16461]  
 
 
    
   
   iv 
TABLE OF CONTENTS  
Table of Contents  ................................ ................................ ................................ ..................  iv 
Abstract  ................................ ................................ ................................ ................................ . ix 
Protocol Synopsis  ................................ ................................ ................................ ..................  xi 
[ADDRESS_1213155] OR INTERVENTION ................................ ..... 4 
1.2.1  Vertebral Body Tethering  ................................ ................................ ................................ ................  4 
1.2.2  Implant  ................................ ................................ ................................ ................................ .............  4 
1.2.3  Surgical Technique  ................................ ................................ ................................ ..........................  4 
1.3 FINDINGS FROM NON-CLINICAL AND CLINICAL STUDIES  ................................ ................................ ..... 6 
1.3.1  Clinical studies  ................................ ................................ ................................ ................................  6 
1.3.2  Non clinical studies  ................................ ................................ ................................ .........................  9 
1.4 RELEVANT LITERATURE AND DATA ................................ ................................ ................................ ..... 9 
1.4.1  Curves Below 50 Degrees With A  High Liklihood of Progression to 50 Degrees  ..........................  9 
1.5 COMPLIANCE STATEMENT  ................................ ................................ ................................ ..................  11 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ............................  11 
2.1 PRIMARY OBJECTIVE (OR AIM)................................ ................................ ................................ ...........  11 
2.2 SECONDARY OBJECTIVES (OR AIM) ................................ ................................ ................................ .... 11 
3 INVESTIGATIONAL PLAN  ................................ ................................ ................................ ..................  11 
3.1 GENERAL SCHEMA OF STUDY DESIGN ................................ ................................ ................................  11 
3.1.1  Screening Phase  ................................ ................................ ................................ ............................  11 
3.1.2  Study Intervention (Surgery)  ................................ ................................ ................................ .........  [ADDRESS_1213156]-operative Follow -up ................................ ................................ ................................ ..............  12 
3.2 ALLOCATION TO TREATMENT GROUPS AND BLINDING  ................................ ................................ ...... 12 
3.3 STUDY DURATION , ENROLLMENT AND NUMBER OF SITES ................................ ................................ . 12 
3.3.1  Duration of Study Participation  ................................ ................................ ................................ .... 12 
3.3.2  Total Number of Study Sites/Total Number of Subjects Projected  ................................ ................  12 
3.4 STUDY POPULATION  ................................ ................................ ................................ ...........................  13 
3.4.1  Inclusion Criteria  ................................ ................................ ................................ ..........................  13 
3.4.2  Exclusion Criteria  ................................ ................................ ................................ .........................  13 
4 STUDY PROCEDURES  ................................ ................................ ................................ ..........................  14 
4.1 SCREENING PHASE  ................................ ................................ ................................ ..............................  14 
4.1.1  Visit 1 (Screening & Pre -operative Visit)  ................................ ................................ .....................  14 
4.2 STUDY TREATMENT PHASE (SURGERY )................................ ................................ ..............................  14 
4.2.1  Visit 2 (Surgical Interven tion)  ................................ ................................ ................................ ....... [ADDRESS_1213157]-SURGICAL FOLLOW -UP PHASE ................................ ................................ ................................ ... 15 
4.3.1  Visit 3 (POD 21)  ................................ ................................ ................................ ............................  15 
4.3.2  Visit 4 (POD 45)  ................................ ................................ ................................ ............................  15 
4.3.3  Visit 5 (POD 90)  ................................ ................................ ................................ ............................  15 
4.4 EXTENDED FOLLOW -UP PHASE  ................................ ................................ ................................ ...........  16 
4.4.1  Visit 6 (POD 180)  ................................ ................................ ................................ ..........................  16 
4.4.2  Visit 7 (POD 365)  ................................ ................................ ................................ ..........................  16 
4.4.3  Visit 8 (POD 730)  ................................ ................................ ................................ ..........................  [ADDRESS_1213158] COMPLETION /WITHDRAWAL  ................................ ................................ ...............................  [ADDRESS_1213159] -operative Course  ................................ ................................ .........  20 
5.1.3  POD 21 Follow up ................................ ................................ ................................ .........................  21 
5.1.4  POD -45 and POD -90 Follow -up ................................ ................................ ................................ .. 21 
5.1.5  POD -180, POD -365, POD -730 Follow -up ................................ ................................ ...................  22 
5.1.6  Laboratory Evaluations  ................................ ................................ ................................ .................  22 
5.1.7  Other Evaluations, Measures  ................................ ................................ ................................ ........  23 
5.2 SAFETY EVALUATION  ................................ ................................ ................................ .........................  23 
5.3 EFFICACY EVALUATION ................................ ................................ ................................ ......................  23 
5.4 CHART REVIEW FOR WITHDRAWN SUBJECTS  ................................ ................................ .....................  24 
6 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ .... 25 
6.1 PRIMARY ENDPOINT  ................................ ................................ ................................ ...........................  25 
6.2 SECONDARY ENDPOINTS  ................................ ................................ ................................ ....................  25 
6.3 STATISTICAL METHODS  ................................ ................................ ................................ ......................  25 
6.3.1  Baseline Data  ................................ ................................ ................................ ................................  25 
6.3.2  Safety Analysis  ................................ ................................ ................................ ...............................  25 
6.3.3  Efficacy Analysis  ................................ ................................ ................................ ...........................  26 
6.3.4  Live Case Demonstration Analysis  ................................ ................................ ................................  26 
6.4 SAMPLE SIZE AND POWER  ................................ ................................ ................................ ..................  26 
6.5 INTERIM ANALYSIS  ................................ ................................ ................................ .............................  27 
6.6 STOPPI[INVESTIGATOR_16442]  ................................ ................................ ................................ ................................  27 
6.6.1  Stoppi[INVESTIGATOR_869279]  (surgery) ................................ ...........  27 
6.6.2  Stoppi[INVESTIGATOR_869280] -related  ................................ ................................ ...........  27 
7 STUDY DEVICE  ................................ ................................ ................................ ................................ ...... 28 
7.1 DESCRIPTION  ................................ ................................ ................................ ................................ ...... 28 
7.2 PACKAGING  ................................ ................................ ................................ ................................ ........  28 
7.3 LABELING AND TRACKING ................................ ................................ ................................ ..................  28 
7.4 INDICATIONS FOR USE ................................ ................................ ................................ ........................  29 
7.4.1  Intent of the Device:  ................................ ................................ ................................ ......................  29 
7.4.2  Patient population:  ................................ ................................ ................................ ........................  29 
7.4.3  Curve types:  ................................ ................................ ................................ ................................ ... 29 
7.4.4  Levels that will be treated:  ................................ ................................ ................................ ............  29 
7.4.5  Growth and skeletal maturity assessment:  ................................ ................................ ....................  29 
7.4.6  Range of curve magnitudes that will be treated:  ................................ ................................ ...........  29 
8 SAFETY MANAGEMENT  ................................ ................................ ................................ .....................  30 
8.1 CLINICAL ADVERSE EVENTS  ................................ ................................ ................................ ..............  30 
8.2 ADVERSE EVENT REPORTING  ................................ ................................ ................................ .............  30 
8.3 DEFINITION OF AN ADVERSE EVENT  ................................ ................................ ................................ ... 30 
8.4 DEFINITION OF A SERIOUS ADVERSE EVENT (SAE)  ................................ ................................ ...........  30 
8.4.1  Relationship of AE/SAE to study intervention  or device  ................................ ...............................  31 
8.5 RECORDING PLAN FOR AES/SAE S ................................ ................................ ................................ ...... 31 
8.6 IRB/IEC  NOTIFICATION OF SAE S AND OTHER UNANTICIPATED PROBLEMS  ................................ ..... 32 
8.6.1  Follow -up report  ................................ ................................ ................................ ...........................  33 
8.7 INVESTIGATOR REPORTING REQUIREMENTS TO IRB  AND FDA  ................................ .........................  33 
8.8 SPONSOR REPORTING REQUIREMENTS TO FDA  AND IRB ................................ ................................ .. 34 
8.9 MEDICAL EMERGENCIES ................................ ................................ ................................ .....................  35 
9 STUD Y ADMINISTRATION  ................................ ................................ ................................ .................  36 
9.1 DATA COLLECTION AND MANAGEMENT  ................................ ................................ ............................  36 
    
   
   vi 
9.2 CONFIDENTIALITY  ................................ ................................ ................................ ..............................  37 
9.3 REGULATORY AND ETHICAL CONSIDERATIONS ................................ ................................ ..................  37 
9.3.1  Data and Safety Monitoring Plan ................................ ................................ ................................ .. 37 
9.3.2  Risk Assessment  ................................ ................................ ................................ .............................  38 
9.3.3  Potential Benefits of Trial Participation  ................................ ................................ .......................  40 
9.3.4  Risk-Benefit Assessment  ................................ ................................ ................................ ................  41 
9.4 RECRUITMENT STRATEGY  ................................ ................................ ................................ ..................  41 
9.5 INFORMED CONSENT /ASSENT AND HIPAA  AUTHORIZATION  ................................ ............................  41 
9.6 PAYMENT TO SUBJECTS /FAMILIES  ................................ ................................ ................................ ...... 41 
10 PUBLICATION  ................................ ................................ ................................ ................................ ........  42 
11 REFERENCES  ................................ ................................ ................................ ................................ .........  43 
12 APPENDIX  ................................ ................................ ................................ ................................ ................  47 
12.1 APPENDIX 1: CLAVIEN -DINDO COMPLICATIONS CLASSIFICATION SYSTEM (FROM DINDO , ET AL .) ..... 47 
 
   
   
   vii 
ABBREVIATIONS AND DEFINITIONS OF TERMS  
Adams’s 
Forward 
Bending Test  Subject stands with their back to the examiner, and bends 
forward at the waist, with knees in extension. The 
examiner looks at the horizontal plane of the spi[INVESTIGATOR_050], and 
measures  the angle created between a rib hump and the 
horizontal plane. This is measured with an inclinometer.  
Adding on  Phenomenon where there is a worsening of the scoliotic 
curve after spi[INVESTIGATOR_869281]. This usually occurs at levels 
distal to the distal end of the spi[INVESTIGATOR_61680].  
AE Adverse Event 
AIS Adolescent Idiopathic Scoliosis  
AT Anterior Tethering  
Bending/Bolst
er x-ray Coronal radiograph of the entire spi[INVESTIGATOR_050], with the patient 
positioned in lateral flexion. The lateral flexion is done 
towards the convex side of the curve, to ‘lessen’ the 
appearance of the curve’s magnitude. This is done either 
standing, with the patient bending under their own power; 
or in the lateral decubitus position, with a pi[INVESTIGATOR_869282] 
‘bolster’ placed at the apex of the convexity of the curve.  
Coronal spi[INVESTIGATOR_050] 
x-ray Radiograph of the coronal plane of the entire spi[INVESTIGATOR_050], 
usually also extending distally to include the femoral 
head/neck . 
HRQOL  Health -Related Quality of Life  
JIS Juvenile Idiopathic Scoliosis  
Lenke 
Classification  Standardized classification system for idiopathic 
scoliosis . The system has three components: 1) main 
curve type (1 -6), 2) lumbar spi[INVESTIGATOR_869283] (A, B, C),  and 
3) sagittal thoracic modifier ( -, N, +) . 
ORC  Office of Research Compliance  
PET Polyethylene Terephthalate  
PFT Pulmonary Function Test  
PSF Posterior Spi[INVESTIGATOR_869284], based on the 
ossification of the iliac crest. Graded on a scale of 0 -5; [ADDRESS_1213160].  
SAE  Serious Adverse Event – any undesirable experience 
associated with use of the medical device that results in 
 
   
   
   viii 
death, is life -threatening, requires inpatient 
hospi[INVESTIGATOR_059], or prolongs existing hospi[INVESTIGATOR_059] . 
Sagittal spi[INVESTIGATOR_050] 
x-ray Radiograph  of the entire spi[INVESTIGATOR_869285].  
Sanders Bone 
Age Standardized method of measuring skeletal maturity that 
is predictive of scoliotic curve progression. This method 
involves analysis of the ossification centers of the hand, 
using an AP rad iograph of the entire hand.  
SOC  Standard of Care  
Thoracic/Lum
bar flexion test  Subject stands with trunk erect while measuring tape is 
placed proximally on the spi[INVESTIGATOR_869286] C7 and 
distally to S1. The subject then bends forward at the 
waist, with knees in extension. Following flexion of the 
vertebrae, using the same bony landmarks, the examiner 
calculates the difference in distance between the starting 
and ending positions.  
Thoracic/Lum
bar lateral 
flexion test  Subject stands erect with the feet fl at on the floor. Place 
one end of a measuring tape on the tip of the middle 
finger and the other on the floor on a point directly 
beneath the middle finger. The patient then laterally 
flexes their trunk. The difference following the lateral 
flexion motion is measured.  
TLSO  Thoraco -lumbo -sacral Orthosis  
UDI Unique Device Identification  
VBT  Vertebral Body Tethering  
    
   
   ix 
ABSTRACT  
Context : 
Scoliosis is a condition in which the spi[INVESTIGATOR_869287] a curvature in the coronal plane. It 
is generally associated with a twisting (axial plane) deformity as well. It can have a variety 
of underlying etiologies and the etiology is used to classify the types of scoliosis. Idiopathic 
scoliosis is sub -classified in two ways: by [CONTACT_869371]. 
Curves between [ADDRESS_1213161] of care for moderate scoliosis in patients with remaining growth is to utilize a 
thoracolumbosa cral orthosis  (TLSO brace)  to prevent progression of deformity. The 
scientific  evidence has supported the efficacy of this intervention in avoidi ng progression of 
the Cobb angle to [ADDRESS_1213162] of wearing an external sign of deformity during adolescence, a key period of 
emotional development. Prior research has identified negative psychosocial effects related to 
wearing a brace in children.  
Recent  evidence has suggested that certain curve patterns will likely progress to 50 degrees 
or more, despi[INVESTIGATOR_12847] a TLSO brace. Sanders, et al.  demonstrated a correlation of 
Cobb angle (greater than 35 degrees) and skeletal maturity  (bone age 4 or less) to the risk of 
progression to 50 degrees or more , despi[INVESTIGATOR_869288] . The evidence supports that the 
current practice of TLSO bracing is not an effective treatment to avoid progression to 50 
degrees in these patients. It i s on this population (thoracic C obb angle greater than 35 
degrees, bone age of 4 or less) that we intend to test the safety and efficacy of anterior 
vertebral body tethering to avoid curve progression to 50 degrees.  
Objectives : 
The objectives of this study are to assess  the safety and feasibility of anterior vertebral body 
tethering surgery to treat idiopathic scoliosis.  
Study Design : 
This is a pi[INVESTIGATOR_799] , non -randomized, open label study of the anterior insertion of a n 
Anterior  Vertebral Tether Device  in pediatric scoliosis. The study will be conducted at a 
single site  - The Children’s Hospi[INVESTIGATOR_6684] . 
Setting/Participants:  
This is a single -site, Sponsor -Investigator led pi[INVESTIGATOR_869289] 8 -16 years.  
 
    
   
   x 
Study Interventions and Measures :  
The study intervention is surgical orthopedic implantation of the A nterior Vertebral Tether 
Device , by [CONTACT_869372]. The primary outcome 
measures include assessments of safety of the insertion procedure and of the device, as well 
as the secondary measure of feasibility by [CONTACT_869373].  Monitoring will be conducted by a Safety Officer , who has extensive 
training and experience in surgical  procedures.  
    
   
   xi 
PROTOCOL SYNOPSIS  
Study Title  Safety and Feasibility of a Vertebral Body Tethering Technique 
for Pediatric Idiopathic Scoliosis  
Funder  Departmental Funds  
Clinical Phase  Pi[INVESTIGATOR_869290] (IS). This study will 
assess whether the intervention ( anterior vertebral tethering ) is a 
safe and feasible method of anterior approach surgery  for spi[INVESTIGATOR_869291] . 
Study Objectives  Primary  
• To determine the safety of anterior vertebral tethering surgery  in 
patients who have been recommended to have surgical 
intervention . 
Secondary  
• To determine the feasibility of anterior vertebral tethering surgery  in 
patients who have been recommended to have surgical 
intervention . 
Test Articles  Anterior Vertebral Teth er Device  
Globus Medical , Inc. 
Transition ™ Stabilization System  
SILC™ Fixation System  
CREO® Thoracolumbar Stabilization System  
Study Design  
 This is a single center prospective, open -label pediatric clinical 
device trial with a single surgical intervention . 
Subject Population  
Key criteria for 
Inclusion and Exclusion:  
 
 
 
 
 
 
 
 
 Inclusion Criteria  
1. Males or females age  8 to 16 years old at time of enrollment 
(inclusive)  
2. Diagnosis of idiopathic scoliosis  
3. Sanders bone age of less than or equal to [ADDRESS_1213163] Population  
Key criteria for 
Inclusion and Exclusion:  
 
 8. Spondylolysis or Spondylolisthesis is permitted, as long as it 
is non -operative, the patient has not had any previous 
surgery for this, and no surgery is planned in the future  
9. Completed standard -of-care procedures as outlined in 
Section 5  
Exclusion Criteria  
1. Pregnancy  (current)  
2. Prior spi[INVESTIGATOR_869292]  
3. MRI abnormalities (including syrinx greater than 4mm, 
Chiari malformation, or tether ed cord)  
4. Neuromuscular, thoracogenic, cardiogenic scoliosis, or any 
other non -idiopathic scoliosis  
5. Associated syndrome, including Marfan Disease or 
Neurofibromatosis  
6. Sanders bone age greater than [ADDRESS_1213164]/family may not be a 
candidate for the intervention  
 
Number Of Subjects  
 The study will be conducted at The Children’s Hospi[INVESTIGATOR_133445], Division of Orthopedics  in up to [ADDRESS_1213165] of patients who present to the 
orthopedic clinic and satisfy the inclusion/exclusion criteria.  
Study Duration  Each subject’s active participation will last post-operatively and 
until approximately  two years after skeletal maturity. The entire 
study is expected to last at least 10 years . 
Study Phases:  
Screening  
 
 
Study Treatment  
 
 
 
 1. Screening phase: Subjects will be screened by [CONTACT_869374] a clinical visit in the orthopedics department. Eligible 
subjects will be approached and if interested, enrolled during 
a routine clinical exam.  
2. Study treatment : The subj ect will undergo surgical 
intervention using an accepted standard -of-care anterior 
approach  using components from  Globus Medical Inc. 
products, the Creo ® Stabilization System, Transition ™ 
Stabilization System , and SILC™ Fixation System . The 
investigati onal device  is identified as the Anterior Vertebral 
Tether Device, comprising  the staples, screws and locking 
 
   
   
   xiii 
 
 
Post-op Follow -Up 
 
 
 caps from  Creo ® and the PET cord from the Transition ™ 
Stabilization System  and SILC™ Fixation System . 
3. Post-operative follow -up: Subjects will be followed at 
regular time points  at 21, 45, and [ADDRESS_1213166]-
operatively, will occur through chart review of subjects, 
through two years beyond attaining skeletal maturity , which 
will be conducted under a separate study . 
Efficacy Evaluations  The exploratory therapeutic efficacy evaluation measurement is 
thoracic Cobb angle (to nearest degree) at the pre-operative visit to 
Cobb angle during follow -up, especially at two years post -op (POD 
730). 
Safety and Feasibility 
Evaluations  We will use phase -specific endpoints to measure safety  and 
feasibility : 
1) Study treatment phase: Any individual -level intraoperative 
events including neuromonitoring events  (loss or change in 
neurological signaling or function) , unanticipated events 
during surgery , and SAEs . 
2) Post-operative active phase: Incidence of infection (within 
[ADDRESS_1213167] -op), pneumothorax , bronchopulmonary plug, or 
any reportable SAE . 
3) Extended follow -up phase: Incidence of over -correction, 
implant failure (measured on serial x -ray), incidence of 
curve progress ion to more t han [ADDRESS_1213168] further spi[INVESTIGATOR_475636] (not related to trauma or 
other issues not related to the initial surgery /disease) . 
Additional follow -up, through two years beyond sk eletal 
maturation, will be conducted by [CONTACT_869375].  
4) Feasibility will be assessed by [CONTACT_869376] . 
Statistical And Analytic 
Plan  The enrollment target of 40 subjects for this initial study of the 
device is based primarily on feasibility rather than statistical 
concerns. As such, analyses will be primarily descriptive for safety 
and feasibility. The Cobb angle, the exploratory therap eutic 
endpoint, will be evaluated as  a continuous variable.  
Data And Safety 
Monitoring Plan  The PI [INVESTIGATOR_869293]. Safety Officer  reports will be forwarded to the IRB during 
continuing review per CHOP O ffice of Research Compliance  
monitoring guidance . Safety reporting will be according to IRB 
 
   
   
   xiv 
SOP 408 and governing FDA guidelines. The PI [INVESTIGATOR_869294].  The PI [INVESTIGATOR_869295].  
 xv   
   
   TABLE OF STUDY PROCEDURES  
Study Phase  Pre-op / 
Screening  Surgery  Post-Operative Phase  Extended Follow -up Phase  
Visit Number  1 2 N/A 3 4 5 6 7 8 
Study Days  Pre-op 
 0 1-44 (or until 
discharge)  21 (+/ - 
21 days)  45 (+/ - 
21 days)  90 (+/ - 
21 days)  180 (+/ - 
90 days)  365 (+/ - 
90 days)  730 (+/ - 
90 days)  
Clinical Care (SOC) Evaluations:  
All 
procedures 
included 
here are 
standard -of 
care for a  
surgical  
orthopedic 
spi[INVESTIGATOR_869296]  X-ray: Hand Bone Age  *         
X-ray: AP /PA and Lat eral 
Spi[INVESTIGATOR_050]  X   * X X X X X 
X-ray: Bending bolster films  X    * * * * * 
MRI: MRI Spi[INVESTIGATOR_050]  (can be 
obtained at any time prior to 
pre-op) X         
Pulmonary Function Test  *       * * 
History and physical exam with 
height and weight  X   X X X X X X 
Anaesthesia Evaluation  X         
Pregnancy Test (as applicable)  X         
Bloodwork  X X X       
Post-operative inpatient 
management by [CONTACT_869377]   X X       
X-ray: AP/PA and Lat eral 
Spi[INVESTIGATOR_050] (performed at discharge)    X       
Research Evaluations:  
Medical Record Review  X X  X X X X X X 
 xvi   
   
    Review Inclusion/Exclusion Criteria  X         
Informed Consent/Assent  X         
Study Specific Physical Exam  X    X X X X X 
SRS 30 Questionnaire  (completed by [CONTACT_1130])  X      X X X 
Clinical Photographs  X      X X X 
Anterior tethering surgery under general 
anaesthesia with spi[INVESTIGATOR_869297]   X        
Intraoperative fluoroscopy (< 1hr)   X        
Complications Evaluation   X X X X X X X X 
KEY:  
X = Procedure is performed at that visit  
* = Optional standard -of-care procedure, performed at discretion of treating physician  
Italics  = Procedures which are performed as standard -of-care 
Bold  = Procedures with greater than minimal risk  
NOTE:  Long -term follow -up through two years after skeletal maturity will take place under a separate observational research protocol  
[ADDRESS_1213169]. It 
is generally associated with a twisting (axial plane) deformity as well. It can have a variety 
of underlying etiologies , and the etiology is used to classify the types of scoliosis. Scoliosis 
related to conditions affecting the nervous system or muscle function are termed 
neuromuscular scoliosis. Neuromuscular scoliosis is often related to conditions such as 
cerebral palsy,  muscular dystrophies, spi[INVESTIGATOR_113163], or paralysis  [1]. Another type of s coliosis 
is congenital scoliosis; scoliosis related to malformation of the bony structures of the spi[INVESTIGATOR_050]. 
Some syndromes are associated with a high incidence of scoliosis including Marfan 
syndrome and neurofibromatosis. These forms of scoliosis are termed s yndromic scoliosis  
[2]. Idiopathic scoliosis is scoliosis not due to any of the above mentioned causes. It is a 
diagnosis of exclusion.  
Idiopathic scoliosis is sub -classified in two ways: by [CONTACT_869378]. Curves between 10 and 25 degrees are considered mild. Curves between 25 and 
50 degrees are classified as moderate. Curves greater than 50 degrees are termed severe. 
Idiopathic scoliosis occurs in 2 -3% of the population with decreasing frequency at higher 
magnitudes of deformity. Idiopathic sc oliosis diagnosed before age 3 is classified as 
infantile idiopathic scoliosis; between 3 and 10, juvenile idiopathic scoliosis; 10 to 18 
adolescent idiopathic scoliosis; greater than 18 is adult idiopathic scoliosis. The diagnosis is 
retained throughout l ife; a juvenile idiopathic scoliosis patient does not become an 
adolescent idiopathic scoliosis patient at age 10.  
Further classification of surgically treated adolescent idiopathic scoliosis has been derived 
by [CONTACT_869379]. [3], in an attempt to guide treatment. The classification system takes into 
account factors such as the location of the deformity (thoracic v s. lumbar v s. both), number 
of curves, the flexibility of the deformity, and the sagittal plane. This classificati on system 
has been widely adopted in medical literature on the condition.  
1.1.[ADDRESS_1213170] 
been implicated  [4]. Biomechanical imbalance leading to asymmetrical spi[INVESTIGATOR_869298] , though there is limited evidence to 
link idiopathic scoliosis progression to a biomechanical cause [5]. Many treatments have 
been proposed to manage the progression of idiopathic scoliosis. Among the various 
treatment methods used,  bracing and  surgical fusion remain the most common treatments to 
alter the natural history of the disease  [6]. Although spi[INVESTIGATOR_869299], it is among 
the most invasive procedures. Loss of motion following fusion and potential for adjacent 
segment deg eneration is a long -term concern.  
In the field of limb deformities, t he concept of growth modulation by a staple in a growing 
child (introduced by [CONTACT_869380] ) is utilized as part of the accepted common practice and as the 
standard of care for management of lim b deformity  [7]. It is presumed that compressive 
implants suc h as staples inhibit growth according to the Hueter -Volkmann principle  [8]. 
[ADDRESS_1213171] been applied successfully for spi[INVESTIGATOR_869300]. 
These devices provide compressive forces on the co nvex side of the curve utilizing  the 
Hueter-Volkman principle; slowing the growth on the convex side of the curve and 
enhancing the growth on the concave side. This effect has been demonstrated  in animal 
models [9]. Furthermore, they have shown to preserve motion at the instrumented levels. 
Radiographic  and chemical analysis performed in the animals have shown that disc function 
is maintained after the application of such a device  [9]. 
1.1.[ADDRESS_1213172] of care  
[IP_ADDRESS]  Moderate Scoliosis (Curves 25 -50 Degrees)  
The care for moderate scoliosis in patients with remaining growth is in a state of clinical 
equipoise. Almost all practitioners utilize one of three strategies: immedia te spi[INVESTIGATOR_61680], 
observation with delayed fusion once a curve reaches fifty degrees, and bracing. Based on 
evaluation of the current body of literature and his clinical experience, he selects immediate 
fusion for those in whom bracing will be ineffectual in preventing progression to [ADDRESS_1213173] inevitable 
progression to 50 degrees and beyond by [CONTACT_869381]. The 
practice of fusion of curves less than 50 degrees is supported by a query of the Harms’ Study 
Group database o n fusion for AIS. This consortium is the largest registry for AIS fusions 
and is made up of the most prominent thought leaders in the field. The registry demonstrates 
that the thoracic Cobb angle of patients who have under gone fusion averages 5 6 degrees 
(std. dev. 13 degrees ). Furthermore, a delay in spi[INVESTIGATOR_869301] a longer 
spi[INVESTIGATOR_869302]  [10-11]. 
The sponsor investigator utilizes bracing in his practice in those patients in whom bracing 
has a probability of altering the natural history. Support  of bracing as a general invention 
derives from recently published studies. In 2010, Katz and colleagues  [12] examined the 
efficacy of bracing and published a study that utilized heat sensors within braces to quantify 
brace wear compliance. In that study , Katz and colleagues [12] determined the brace success 
rate to be 82% in patients who wore their brace for more than 12 hours per day. In 2013, 
Wein stein and colleagues  [13] demonstrated an improvement over the natural history with 
brace treatment and a correlation between hours of brace wear and efficacy of bracing in 
adolescent idiopathic scoliosis ( AIS). 
The prospective studies of bracing have  led to analysis  of various subpopulations treated 
with bracing and published literature suggests that bracing in ineffectual for those patients 
who are early in the skeletal maturation process. The most important difference in the results 
presented by [CONTACT_869382] [13] and Katz and colleagues [12] and the proposed 
study is the  level of maturity (and therefore natural history) of the treatment population. The 
average age of initiation of bracing in both the Weinstein  et al.  and Katz  et al.  studies was 
12.7 years. In a subsequent study of AIS patients treated with bracing  from th e Katz et al. 
study , Karol and colleagues demonstrated a more than five-fold increased risk of bracing 
failure in Risser 0 patients compared to  Risser 1 patients [14]. The study results of Karol  et 
al. and others suggest that there may be a level of skeletal immaturity below which bracing 
3 
 
   cannot alter the natural history of moderate idiopathic scoliosis [15]. The study reported that 
63% of patients with Risser 0 and open triradiate cartilage progressed to the point of 
requiring a fusion. The efficacy of bracing in this  cohort was significantly less than those 
with closed triradiate cartilages (P<0.001). Furthermore, those patients with Risser 0, open 
triradiate cartilage, and a Cobb angle of 30 degrees or greater had a 74% incidence of 
progression to fusion. Jarvis and colleagues [16] reported that fusion was avoided in only 
49% of those patients with  juvenile idiopathic scoliosis (JIS) treated with bracing, which 
raises the question of whether bracing has any impact on the natural history in JIS. Charles  
et al.  further stratified JIS by [CONTACT_869383] [17]. The study showed that curves more than 30 
degrees prior to the puberty gr owth spurt progressed to a magnitude requiring surgery in 
100% of cases despi[INVESTIGATOR_869303].  
For these reasons, the practice of the Sponsor -Investigator is to perform a spi[INVESTIGATOR_869304] a curve less than [ADDRESS_1213174] a high lik elihood of 
progression to a Cobb angle beyond 50 degrees and in whom bracing would likely fail. The 
decision making by [CONTACT_978] [INVESTIGATOR_869305]: a) those patients who meet 
the parameters for inclusion would otherwise be offered a spi[INVESTIGATOR_28947] l fusion, and b) those who do 
not meet the inclusion criteria would be recommended bracing or observation.  
Additional negative aspects of brace management in inappropriate populations are coming to 
light. If treated with a brace, many idiopathic scoliosis patients would conceivably be 
subjected to years of brace wear and the cost and psychological factors inherent therein. 
Brace treatment include s the potentially negative psychosocial impact of wearing an external 
sign of deformity during adolescence, a key  period of emotional development. Prior research 
has identified negative psychosocial effects related to wearing a brace in children [18]. Such 
ramifications were further explored in a recent study by [CONTACT_869384] [19], who 
found that the patients experienced a moderate level of stress specifically related to brace 
wear despi[INVESTIGATOR_869306]. From a patie nt 
reported outcome point of view, the treatment is worse than the disease.  
 
[IP_ADDRESS]  Severe Scoliosis (Curves 50 Degrees and Greater)  
Spi[INVESTIGATOR_869307] 50 degrees in AIS and JIS. 
Posterior spi[INVESTIGATOR_61680] (PSF) invol ves a midline approach to the back, placement of spi[INVESTIGATOR_869308] (usually pedicle screws), and fusion with bone graft across the posterior laminae. 
The course of treatment is predictable and safe. Newton et al. reported on the treatment of 
the most common s ubtype of AIS – Lenke 1 curves – which comprise about half of all AIS 
cases. He reported that a posterior spi[INVESTIGATOR_869309] a four hour surgery with a five 
day hospi[INVESTIGATOR_854603] a blood loss of approximately 800cc [20]. Anterior spi[INVESTIGATOR_869310] a thoracotomy (open procedure) or thoracoscopy. 
Thoracoscopic anterior spi[INVESTIGATOR_869311] [21]. 
[ADDRESS_1213175] or Intervention  
1.2.1 Vertebral Body T ethering  
Vertebral body tethering (VBT)  will be performed via an anterior thoracoscopic approach 
(see “Surgical Technique” below). This approach  is safe  and effec tive at achieving access to 
the spi[INVESTIGATOR_869312], and has predictable perioperative course and 
little to no long -term impacts on health and function. This surgical approach is utilized as a 
common approach for the current standard of care  anterior -type spi[INVESTIGATOR_61680] [21, 22]. 
Thoracoscopic anterior approaches do not seem to carry any increased risk over other 
approaches for spi[INVESTIGATOR_61680], namely posterior spi[INVESTIGATOR_869313]. 
The reason it is not uniformly utilized is tha t the fusion is less reliable in this approach with 
the pseud o-arthrosis rate in thoracosc opic surgery reported at 11% v s. 3% in posterior spi[INVESTIGATOR_260845] [20]. This concern is irrelevant in VBT as fusion is not the goal.  
1.2.2 Implant  
The implant s utilized are comprise d of components from Globus Medical , Inc. , the Creo ® 
Stabilization System, Transition ™ Stabilization System , and SILC™ Fixation System  
systems . The Creo ® system  is designed  and indicated  to be used in anterior thoracoscopic 
spi[INVESTIGATOR_869314]. We anticipate placing centering staples , screws and 
locking caps  from the Creo ® system in a manner identical to how they are approved for use. 
However, rather than performing a discectomy, placing bone graft, and placing a rigid rod, 
we will place a flexible Polyethylene Terephthalate (PET) cord  (from th e Globus Medical , 
Inc. Transition ™ Stabilization System  or SILC™ Fixation System ). The cord s are approved 
as part of posterior spi[INVESTIGATOR_869315] s. The implanted investigational device will be 
composed of the staples, screws and locking caps  from the Creo ® system and the PET cord 
from the Transition ™ Stabilization System  or SILC™ Fixation System , and will be referred 
to in this IDE application as the Anterior Vertebral Tether Device (AVTD). Zimmer Spi[INVESTIGATOR_050], 
Inc. has a posterior PET cord as part of their Dynesis ® system but they do not have an 
anterior thoracoscopic implant system that it can be used with. Some surgeons have 
suggested modi fying  posterior s crews from the Dynesis ® system for anterior use for 
vertebral tethering but these screws do not have sizing for pediatric indications, as the 
Creo ® system does. Furthermore, the Dynesis ® system does not have a centering/stabilizing 
staple , which  is a common component of anterior  spi[INVESTIGATOR_869316].  In August 
2019, the FDA approved The Tether ™ – Vertebral Body Tethering System, developed by 
[CONTACT_869385][INVESTIGATOR_050].  
1.2.3 Surgical Technique  
The surgical technique has been described by [CONTACT_869386],  et al.  [23, 24]: 
The patient is intubated with a double lumen endotracheal tube with fiber optic 
assistance. A Foley catheter is placed. The patient is positioned in a lateral decubitus 
position with the operative  (convex curve)  side facing  up. The operative flank is 
prepped and draped from midline anteriorly to midline posteriorly. Flu oroscopic 
assis tance is utilized to mark out the location of the various vertebra and three 5mm 
incisions are made to insert the ports in triangular fashion . The apex  incision is made 
[ADDRESS_1213176] port  a camera is introduced, harmonic scalpel  through the second , and 
endoscopic “peanut” is placed through the third incision. The pleura is dissected off 
the vertebral bodies laterally  along the length of the curve , and anteriorly to the rib 
heads . Care is taken to identify and coagulate the segmental vessels. A 15mm port is 
then inserted over the most cephalad vertebral body ready to be tethered.  Over the 
anterior aspect  of the most cephalad vertebral body , a 3 prong staple  (Creo ® 
Stabilization S ystem , Globus Medical , Inc. ) is introduced while maintaining caution 
that the staple is not introduced in the foramen. Using fluoroscopy the position of the 
staple is confirmed , and then a 5.2mm tap  is used to create a screw hole under 
fluoroscopic guidance. The tap is begun on the c onvex side of the curve towards the 
concave  side, across the anterolateral portion of the vertebral body. Next, an 
appropriately sized screw ( Creo ® Stabilization  System , Globus Medical , Inc. ) is 
placed, with position of the screw confirmed by [CONTACT_476761]. Utilizing the same skin 
incision, the 15mm port is moved to the  next intercostal space . The vessel ligation, 
staple placement, tap, and screw placement are then repeated at the next vertebral 
body - moving cephalad to caudad. Generally, up to [ADDRESS_1213177]  
(Transition ™ Stabilization System  or SILC™ Fixation System , Globus Medical , Inc. ) 
through the tulips of all of the screws. The set screw  (Creo ® Stabilization System , 
Globus Medical , Inc. ) is then placed on the most caudal screw tulip using a T -handle 
pusher. The set screw is locked in place  using a locking cap ( Creo ® Stabilization 
System , Globus Medical , Inc. ), thereby [CONTACT_869387] . Correction is achieved by [CONTACT_869388][INVESTIGATOR_050]. Once the correction achieved is satisfactory to the surgeon, the set screws 
are tightened on each screw tulip - moving caudad to cephalad. Flu oroscopic images 
should be obtained after each scr ew is tightened, to confirm curve correct ion. These 
fluoroscopic images also confirm that there is no pulling out, plowing, or other 
untoward changes in the screw placements in the vertebral bodies.  
Once all screws have been tightened, global AP and Latera l x-rays of the spi[INVESTIGATOR_869317]. Once satisfactory correction is 
confirmed in this manner, the PET cord  should be trimmed, to leave about 2cm at 
either end to accommodate any future adjustment  if necessary. At this juncture, the 
implantation of the investigational device, the Anterior Vertebral Tether Device, 
composed of staples, screws and set screws from the Creo ® Stabilization System, and 
the PET cord from the Transition ™ Stabilization System  or SILC™ Fixation System , 
is complete.  An attempt should be made to re -approximate the pleura, though this is 
difficult with the implant. A chest tube should be placed in one of the 5mm port sites. 
The hemithorax is then irrigated, the lung is re -inflated u nder direct vision, and the 
incisions are closed in layers.  
6 
 
   1.3 Findings from Non -Clinical and Clinical Studies  
1.3.1 Clinical studies  
When anterior spi[INVESTIGATOR_869318], the thoracic or the lumbar curve , requires a fusion [25]. We are proposing similar 
indications and applications for vertebral body tethering – a single thoracic curve requiring 
treatment. Anterior spi[INVESTIGATOR_869319]. The 
approach for anterior spi[INVESTIGATOR_869320]. The thoracoscopic approach is less invasive than its alt ernative, an open 
thoracotomy. Newton  et al.  reported on five year results of thoracoscopic anterior fusion 
showing that Cobb angle correction averaged 56% [22, 26], and total lung capacity at 91% 
of expected. Th ese results were not different than the two year outcomes in the same 
patients , suggesting that any slight negative impact of anterior thoracoscopy did not lead to a 
progressive decline in pulmonary function. Furthermore, although open anterior spi[INVESTIGATOR_869321] a significant decline in objective measurements in pulmonary 
function, thoracoscopic anterior surgery was not different in its impact on pulmonary 
function than posterior spi[INVESTIGATOR_61680] [27, 28]. Faro  et al.  demonstrated that pulmonary 
function declines three  months after both open and thoracoscopic anterior scoliosis surgery 
but recovers by [CONTACT_235850] -op in thoracoscopic surgery but not in open anterior surgery 
[29]. 
In a comparison of the three approaches for fusi on of the thoracic spi[INVESTIGATOR_869322] (open 
anterior, thoracoscopic anterior, and posterior), Newton et al. in another study reported that 
Cobb angle correction (57%) was similar in all groups, blood loss and incidence of 
transfusion was greater but surgical ti me was less in the posterior group, and SRS -22 scores 
were equivalent [20]. Furthermore, they reported decreased pulmonary function in the open 
anterior groups but similar pulmonary function tests ( PFTs ) in posterior and thoracoscopic 
patients. Lonner et  al. also addressed the impact of surgical approach on pulmonary function 
[25]. The authors reported a decrease in forced expi[INVESTIGATOR_869323] 1 second (FEV1) and 
functional vital capacity (FVC) as a percent of expected by 4 -5% but an increase in total 
lung capacity (TLC) of 3% (Table s 1 and 2) . These changes are of minimal clinical 
significance.  
Table 1: Demographics ( adapted from Lonner et al, 2015)  
Approach Type  N Sex Distribution  Mean Age at 
Surgery 
(Range)*  Mean 
Numbers 
Levels Fused  Lenke Curve 
Type 
Thoracotomy  68 61 female, 7 male  14.3 (10 -21) 6.6 1 
Thoracoscopic  44 39 female, 5 male  13.9 (10 -18) 6.1 1 
Thoracoabdominal  19 18 female, 1 male  14.8 (13 -18) 4.1 5 
*Not significantly different.  
  
7 
 
   Table 2: Mean Percent -predicted Values Preoperatively to Follow -up (adapted from Lonner et al, 
2015)  
 Percent predicted  
FEV1  Percent predicted  
FVC Percent predicted  
TLC  
Thoracotomy  
Mean pre -operative  83.3 88.1 85.6 
Mean follow -up 72.3 75.1 77.6 
 (Pre-post) -11.0 -13.0 -8.0 
P <0.001   <0.001   ≤ 0.001   
Thoracoscopic  
Mean pre -operative  82.5 87.2 85.0 
Mean follow -up 78.1 82.5 88.2 
 -4.4 -4.7 3.2 
P <0.004  NS NS 
Thoracoabdominal  
Mean pre -operative  90.3 93.7 94.7 
Mean follow -up 83.5 87.7 95.1 
 -6.8 -6.0 0.4 
P NS NS NS 
FEV1 indicates forced expi[INVESTIGATOR_3741] 1 second; FVC, forced vital capacity; NS, non -
significant; TLC, total lung capacity  
There is room for improvement over the outcomes of posterior spi[INVESTIGATOR_61680]. In particular, 
the durability of the procedure is coming into question. Posterior pedicle screw constructs 
came into popularity in the early 2000’s and new [ADDRESS_1213178] 10% of AIS fusions require 
revision surgery by [ADDRESS_1213179] -op and that this tren d is progressive  [30] (Figure 1) . 
 
8 
 
   Figure 1: Re -operation rates  (“Survi val Curve”)  of posterior spi[INVESTIGATOR_869324]. 
(Pers onal Communication from Peter Newton)  
 
Other authors have also reported on high long term re -operation rates following AIS fusion 
surgery r anging from 4.6% to 19%  [31-33]. One theory is that a fusion imparts increased 
stress on unfused segments below a fusion. Marks et al. have shown that patients will retain 
total lumbar motion after a posterior spi[INVESTIGATOR_869325] 
[34]. The authors postulate that increased motion may lead to degeneration of discs and facet 
joints. These findings o f supraphysiologic motion below a posterior spi[INVESTIGATOR_869326]. Green et al. have studied 
the health of intervertebral discs below a spi[INVESTIGATOR_869327] 11.8 years following 
posterior spi[INVESTIGATOR_61680] [35]. The authors found that disc dege neration was occurring in 85% 
of patients when graded by [CONTACT_869389], an objective validated measure of disc 
degeneration  [35]. Vertebral tether surgery will allow for continued motion of the 
instrumented levels and thus avoid the long lever -arm effect of a long fusion that may be 
contributing to early degeneration. Additional reports have questioned the durability of 
posterior spi[INVESTIGATOR_61680]. Upasani et al. reported on increased pain in patients at five years 
post-spi[INVESTIGATOR_869328] [36]. Lastly, posterior spi[INVESTIGATOR_869329],  the population in whom we are proposing 
vertebral tethering, are at increased risk of complications and re -operation. Sponseller et al. 
reported that patients with open triradiate cartilages undergoing spi[INVESTIGATOR_869330] “adding on ” (development of deformity below a fusion) and the 
response of the un -instrumented lumbar curve is less predictable [37]. 
Ideally, longitudinal outc omes of current standards of care including anterior thoracoscopic 
and posterior pedicle screw instrumented fusion would be used as a standard against which 
new technology can be compared. However, such data is a half century away. Furthermore, 
the pace of  change and improvement in spi[INVESTIGATOR_869331]  [38]. 

[ADDRESS_1213180] been several animal studies of vertebral tethering. Peter Newton and colleagues 
at The University of [LOCATION_004] at San Diego and Rady Children’s Hospi[INVESTIGATOR_869332] [39-41]. The first study the authors 
published was in an immature bovine model [40]. They utilized a stainless steel tether. They 
demonstrated those animals who had a sham surgery without placement of the tether did not 
develop a curvature while those with placement of two rods did develop a curve. This was 
offered as a proof of concept that tension of a tether could alter growth and change 
alignment. In the porcine model, the investigators  demonstrated the ability of a spi[INVESTIGATOR_869333], 
offering further evidence of the effect of growth in contributing to the deformity rather than 
tension of the implant alone [42]. Further evidence of the effect of growth driving the 
change in alignment was offered in a subsequent study of the bovine model [39]. They 
demonstrated equivalent deformity magnitude after 12 months between groups in which the 
tether was tensioned and those in which it was placed without tension.  
1.4 Relevant Literature and Data  
The natural history of scoliosis after ma turity has been described in several populations 
treated non -operatively and followed longitudinally. One cohort is from Scandinavia and 
was reported by [CONTACT_869390] [43]. The other  is from Iowa and was reported  
by [CONTACT_869391]  [44, 45]. Nachemson reported a cohort of [ADDRESS_1213181] -infectious scoliosis, and idiopathic scoliosis [46]. Decreased 
life expectancy was reported in this group. A subsequent sub -analysis of only the idiopathic 
scoliosis patients in this group revealed that there was no increase in mortality compared to 
the general population. Weinstein et al. reported a group of idiopathic scoliosis patient s 
treated with observation [45]. They showed that, despi[INVESTIGATOR_869334], 
there was no increase in mortality rates compared to the aged matched general population. 
Furthermore, they identified Cobb angle greater than 50  degrees as a predictor of continued 
progression in adulthood. Greater than 85% of these patients progressed at a rate of ~1.1 
degree s per year. Weinstein demonstrated a cobb angle greater than 50 degrees as a factor 
predictive of further progression in ad olescents in a subsequent study  [44]. This forms the 
basis for current indications of surgical fusion for curve s greater than [ADDRESS_1213182] elucidated which curves in immature patients will progress to 50 
degree s before reaching skeletal maturity. Rather than taking a reactive approach to these 
curves, we propose early treatment of this population with vertebral tethering. Dimeglio et 
al. demonstrated that immature patients with idiopathic scoliosis with a Cobb an gle of 30 
degrees or greater prior to their pubertal growth spurt will universally progress to 50 degrees 
by [CONTACT_869392]  [47]. Dimeglio suggests sev eral measures for identifying th e onset of 
10 
 
   pubertal growth spurt including the changes of various bone growth centers remote from the 
spi[INVESTIGATOR_050]. These include the appearance (radiographically) of the sesamoid bone in the thumb, 
the presence  of two distinct ossification centers in the olecranon (elbow), and an open tri -
radiate cartilage (hip socket). Sanders et al. have also demonstrated a correlation of risk of 
progression to a Cobb angle of 50 degrees between markers of skeletal maturity an d Cobb 
angle  [48]. They developed an easily applied sco ring system of 1 -7 to a hand x -ray. The 
advantage of a hand x -ray is that it encompasses a large number of growth centers, does not 
require additional training of radiology personnel, and is remote from more radiosensitive 
organs. The maturity based progre ssion assessment derived by [CONTACT_869393] a risk of 
progression to a Cobb angle of 50 degrees or more . It is this risk of progression to 50 
degrees on which we base o ur treatment decision for vertebral body tethering . Table 3  
illustrates that there is si gnificant risk for progression if a patient’s curve is above [ADDRESS_1213183] selected an upper limit of 60 degrees due to the theoretical concern of achieving 
higher amounts of correction during periods of limited growth. In retrospective series by 
[CONTACT_869394]., the average Cobb angle of treated curves was  44 degrees  [23, 24]. 
Table 3: Projected risk of progression of scoliosis to above 50 degrees, based on curve 
magnitude and bone age.  (From Sanders, et al. 2008 ) 
 

11 
 
   1.5 Compliance Statement  
This study will be conducted in full accordance with all applicable Children’s Hospi[INVESTIGATOR_5765] 45 CFR 46, 21 CFR Parts 50, 54, 56, 312, 314 and 812. All epi[INVESTIGATOR_869335].  
The investigators will perform the study in accordance with this protocol, will obtain 
consent and assent, and will report unanticipated problems involv ing risks to subjects or 
others in accordance with The Children’s Hospi[INVESTIGATOR_175353]. Collection, recording, and reporting of data will be 
accurate and will ensure the privacy, health, and welf are of research subjects during and 
after the study.  
2 STUDY OBJECTIVES  
The purpose of the study is to determine the safety and feasibility of Anterior Vertebral 
Body Tethering surgery on patients with idiopathic scoliosis . 
2.1 Primary Objective (or Aim)  
The pri mary objective  is to assess the safety  of Anterior Vertebral Body Tethering  surgery  
in patients recommended for surgery  in the immediate post -operative period.  
2.2 Secondary Objectives (or Aim)  
The secondary  objective is to assess feasibility by [CONTACT_869395] e ability to successfully 
implant the investigational device  in study subjects  who have been recommended for 
surgical intervention . 
[ADDRESS_1213184] been indicated for scoliosis surgery by [CONTACT_1963] . Patients 
who satisfy the inclusion and exclusion criteria will be approached and presented 
information about the clinical  study. Those subjects and families who are  interested in 
pursuing the clinical study will be enrolled by [CONTACT_65241]/assent. This 
phase will last one day. 
3.1.2 Study Intervention (Surgery)  
Enrolled patients who have completed the pre -operative c ourse for anterior spi[INVESTIGATOR_79477] 
(pre-operative SOC and pre-operative study procedures) will undergo the study intervention 
comprising implantation of staples, anterior vertebral body  screws , locking caps  and PET 
cord (the Anterior Vertebral Tether Device)  under general anesthesia. This phase will last 1 
day (day of surgery). This surgical intervention is estimated to last about 5.5 hours; 2.[ADDRESS_1213185] -of-care clinical follow -up visits for spi[INVESTIGATOR_869336]. The three  time-points are a POD 21 wound check, POD -45 
clinical visit, and a POD -90 clinical visit. During these three clinical visits physical exams, 
radiographs,  and AE/SAE data will be collected  depending on the visit . POD 2 -44 will be 
monitored for known complications and AE/SAEs only , as there will be no clinical 
outcomes data to collect during this time . This data wi ll be abstracted from the medical 
records. In addition, the patient will be under SOC post -operative care for patients who have 
undergone anterior spi[INVESTIGATOR_61691] . Data from any SOC interventions will also be abstracted  
from the medical record . 
In unique ci rcumstances, the Investigator may determine it is necessary for the Subject to be 
seen for a follow -up visit(s) at an outside institution due to geographic, travel, other 
restrictions. In such a case the Investigator will communicate with the physician eva luating 
the Subject at the outside institution and Subject to ensure all necessary data points and 
AE/SAE information are captured. If possible copi[INVESTIGATOR_869337]’s medical record for this 
visit will be obtained by [CONTACT_3476].  
3.[ADDRESS_1213186] perform  the intervention. Introduction of a sham  or 
placebo group would be  impractical and unethical in thi s context. The study will only enroll 
one cohort  - the anterior tethering (intervention ) cohort.  
3.[ADDRESS_1213187] eight  visits  over a two year (730 day)  period : one 
day for recruitment/consent, one day for the study intervention (surgery), one day for  each 
visit:  POD21, POD45 , POD90 , POD180, POD365, and POD730 . These visits follow the 
schedule for a patient’s standard -of-care follow -up for  anter ior spi[INVESTIGATOR_61691]. Any off -study 
visits within the study window will not be captured, unless they are related to an AE/SAE. 
There is a three -week grace period for post-operative study visits,  and a 90 day grace period 
for extended follow -up visits,  making  the initial study participation period 730 + [ADDRESS_1213188] through a separate observational study .  
3.3.2 Total Number of Study Sites/Total Number of Subjects Projected  
The study will be conducted at The Children’s Hospi[INVESTIGATOR_6684].  
[ADDRESS_1213189] to enroll about 5 -10 
patients per year.  
3.4 Study Population  
3.4.1 Inclusion Criteria  
1) Males or females age  8 to 16 years old at time of enrollment (inclusive)  
2) Diagnosis of idiopathic scoliosis  
3) Sanders bone age of less than or equal to 4  
4) Thoracic curve of greater than or equal to 35 degrees  and less than or equal to  60 degrees  
5) Lumbar curve less than 35 degrees  
6) Patient has already been identified for  and recommended to have  surgical intervention  
7) Spi[INVESTIGATOR_869338]  
8) Spondylolysis or Spondylolisthesis is permitted, as long as it is non -operative, the 
patient has not had any previous surgery for this, and no surgery is planned in the future  
9) Completed standard -of-care procedures, as outlined in the Table of Study Procedures  
10) Subject consent and (if applicable) assent  
3.4.2 Exclusion Criteria  
1) Pregnancy  (current)  
2) Prior spi[INVESTIGATOR_869292]  
3) MRI abnormalities ( could includ e syrinx greater than 4mm, Chiari malformation, or 
tethered cord)  
4) Neuromuscular, thoracogenic, cardiogenic scoliosis, or any other non-idiopathic 
scoliosis  
5) Associated syndrome, including Marfan syndrome  or neurofibromatosis  
6) Sande rs bone age greater than 4  
7) Thoracic curve less than 35 degrees  or greater than  60 degrees  
8) Lumbar curve greater than or equal to 35 degrees  
9) Unable or unwilling to firmly commit to returning for required follow -up visits  
14 
 
   10) Investigator judgement that the subje ct/family may not be a candidate for the 
intervention  
Subjects that do not meet all of the enrollment criteria may not be enrolled. Any violations 
of these criteria must be reported in accordance with IRB Policies and Procedures.  
4 STUDY PROCEDURES  
4.1 Screening  Phase  
4.1.1 Visit 1  (Screening  & Pre -operative  Visit)  
• Informed consent/assent  
• Medical record and x -ray review  for eligibility screening (research)  
• History and physical exam with height and weight  
• Research specific p hysical exam (research ) 
• Anesthesia evaluation  
• Pulmonary function test (completed at treating physician’s discretion)  
• Bloodwork ( outlined in Section 5.1. 6) 
• Pregnancy test, as applicable  
• X-ray: bending bolster , AP/PA, lateral spi[INVESTIGATOR_050], and hand bone age  
• SRS 30  Questionnaire  (research)  
• Clinical photographs  (research)  
• Medical record and x-ray information abstraction  (research)  
4.2 Study Treatment Phase (Surgery)  
4.2.1 Visit 2 (Surgical Intervention)  
This phase includes the surgical intervention  - vertebral body tethering through anterior 
thoracoscopic approach under general anesthesia  and fluoroscopic guidance . This process is  
described in Section 2. 
Data from the surgery will be abstracted by [CONTACT_869396]. Intra -operative data (including radiog raphs) will also be abstracted from the 
medical record/surgical logs. Results from the surgery and inpatient stay will be abstracted 
at the time of discharge, except for those events which fall under the reporting guidelines of 
AE/SAEs. All AE/SAEs will be  reported according to reporting guidelines listed in Section 
8. 
[ADDRESS_1213190] -operative complications/SAE, as well as three  
SOC clinical  visits in this phase , where the subject will also undergo a research visit . This 
phase also includes all inpatient recovery in the post -operative period, which includes post -
operative bloodwork and radiographs. Information from SOC  procedures will also be 
abstracted from the medical records and radiology database s. 
4.3.1 Visit 3 (POD 21)  
• X-ray: AP/PA and lateral spi[INVESTIGATOR_050] (completed at treating physician’s discretion)  
• History and physical exam with height and weight  
• Medical record review and abstraction  (research)  
• Complications review  (research)  
4.3.2 Visit 4 (POD 45)  
• X-ray: AP/PA and lateral spi[INVESTIGATOR_050]  
• X-ray: Bending bolster films (completed at treating physician’s discretion)  
• History and physical exam with height and weight  
• Research specific p hysical exam (research)  
• Medical record review  and abstraction  (research)  
• X-ray re view  and abstraction  (research)  
• Complications review  (research)  
4.3.3 Visit 5 (POD 90)  
• X-ray: AP/PA and lateral spi[INVESTIGATOR_050]  
• X-ray: Bending bolster films (completed at treating physician’s discretion)  
• History and physical exam with height and weight  
• Research specific p hysical exam (research)  
• Medical record review and abstraction  (research)  
• X-ray review and abstraction  (research)  
• Complications review  (research)  
[ADDRESS_1213191] -operative complications/SAE s, as well as t hree 
SOC clinical visits  in this two year phase , where the subject will also undergo a research 
visit. Information from SOC  procedures will also be abstracted from the medical records and 
radiology databases.  
4.4.1 Visit 6 (POD 180) 
• X-ray: AP/PA and lateral spi[INVESTIGATOR_050]  
• X-ray: Bending bolster films (completed at treating physician’s discretion)  
• History and physical exam with height and we ight 
• Research specific p hysical exam (research)  
• Medical record review and abstraction  (research)  
• X-ray review and abstraction  (research)  
• Complications review  (research)  
• Clinical photographs (research)  
• SRS 30 Questionnaire (research)  
4.4.2 Visit 7 (POD 365)  
• X-ray: AP/PA and lateral spi[INVESTIGATOR_050]  
• X-ray: Bending bolster films (completed at treating physician’s discretion)  
• Pulmonary function test (completed at treating physician’s discretion)  
• History and physical exam with height and weight  
• Research specific p hysical exam (r esearch)  
• Medical record review and abstraction  (research)  
• X-ray review and abstraction  (research)  
• Complications review  (research)  
• Clinical photographs (research)  
• SRS 30 Questionnaire (research)  
17 
 
   4.4.3 Visit 8 (POD 730) 
• X-ray: AP/PA and lateral spi[INVESTIGATOR_050]  
• X-ray: Bending bolster films (completed at treating physician’s discretion)  
• Pulmonary function test (completed at treating physician’s discretion)  
• History and physical exam with height and weight  
• Research specific p hysical exam (research)  
• Medical record review an d abstraction  (research)  
• X-ray review and abstraction  (research)  
• Complications review  (research)  
• Clinical photographs (research)  
• SRS 30 Questionnaire (research)  
• Study completion CRF (research)  
4.5 Long -Term Follow -up Phase  
We are planning  a long -term follow -up phase (LTFU) through approximately two years 
after each subject reaches skeletal maturity. Following the extended follow -up phase 
(approximately two years post -operative) , the LTFU will be an observational study 
involving chart revie w. This will be performed under a separate research study.  Device -
related SAEs  and relevant data to assess safety and feasibility endpoints up to two years 
after skeletal maturity will be reported in accordance with FDA requirements .  
4.6 Unscheduled Visits  
Unscheduled clinic visits will be made through the department ’s/hospi[INVESTIGATOR_307] ’s clinical 
schedulers. As part of clinical care, physical evaluations and tests may be conducted. At 
these visits, the only research procedures performed will be  medical record /radiogra phic 
record abstraction and complications review.  
4.[ADDRESS_1213192] Completion/Withdrawal  
Subjects may withdraw from the study at any time without prejudice to their care. They may 
also be discontinued from the study at the discretion of the Investigator for lack of  adherence 
to study treatment or visit schedules, AEs, or due to non -compliance. However, in order to 
collect important study -related data for this investigational device, as much as is feasible, the 
Investigator and study team will make efforts to follow -up subjects who do not strictly 
adhere to timely visit schedules. The Investigator  and study team  may do this via emails, 
phone calls, or letters. The Investigator may also withdraw subjects who violate the study 
[ADDRESS_1213193] -operative follow -up phases due 
to AEs/SAEs, such as tether failure or implant re -operation, will no longer be followed at 
study -specific visits . These subjects have the option to consent and allow for continued 
monitoring by [CONTACT_869397] -year 
Extended Follow -up Phase. Subjects who are withdrawn from the study also have the option 
to enroll in a separate LTFU observational study .  
4.7.[ADDRESS_1213194] addressed to the site’s PI.  A ‘Study Completion 
CRF’ will be filed for each subject.  
4.[ADDRESS_1213195]’s surgery. Selection of an 
eligible subject, consent process, conduct of the surgical procedure, and subsequent follow -
up visits and monitoring will be performed as defined in the protocol and similarly to 
subjects who are not pa rticipating in the live case demonstration.  
 
19 
 
   5 STUDY EVALUATIONS AND MEASUREMENTS  
5.1 Screening and Monitoring Evaluations and Measurements  
5.1.1 Pre-operative Visit  
[IP_ADDRESS]  Screening  
• Potential subject  is identified by [CONTACT_176344]  (match inclusion /exclusion 
criteria , surgical candidate ) 
• Complete i nformed consent /assent  
• Review inclusion /exclusion criteria , complete inclusion /exclusion  checklist  
• Complete s ubject screening CRF  
[IP_ADDRESS]  Pre-operative  Medical Record/Radiograph Review  
• Name  
• Age 
• Sex 
• Race  
• Ethnicity  
• Date of birth 
• MRN  
• Diagnosis  
• Clinical and surgical history (including history of pregnancy)  
• Radiographic information and reports (including pre -operative  coronal /sagittal ; spi[INVESTIGATOR_65034])  
• PFT data (if available)  
[IP_ADDRESS]  Pre-operative  Anesthesia Evaluation and Bloodwork  (abstracted fr om medical 
record)  
• Result of anesthesia evaluation : fitness for surgery, special notes  
• Bloodwork results/levels  
[IP_ADDRESS]  Pre-operative  Physical Examination  
• Standing height  
• Weight  
20 
 
   • BMI  – (reported as % ) as calculated by [CONTACT_331820]  
• Trunk flexibility measurements (standardized): Adam’s Forward bending 
test/inclinometer (degrees), thoracic and lumbar flexion (cm) , thoracic and lumbar 
lateral flexion (cm)  
• Data abstracted from clinical care exam (medi cal records, radiology reports, 
pulmonology tests)  
• SRS 30  Questionnaire  
• Clinical photographs  
[IP_ADDRESS]  Pre-operative  Radiographs  (abstracted from medical record)  
• AP/PA and lateral spi[INVESTIGATOR_255552]  
• Bone age hand radiograph (performed at physician discretion)  
• Bending bolster films  
5.1.[ADDRESS_1213196] -operative Course  
[IP_ADDRESS]  Intra - and Post -operative  Procedures  
• Anterior tethering surgery under general anesthesia with spi[INVESTIGATOR_869297]  
• Intraoperative fluoroscopy (<1 hour)  
• AP/PA and lateral  standing radiographs of the spi[INVESTIGATOR_050]  
[IP_ADDRESS]  Intraoperative Data (abstracted from medical record)  
• Operative efficiency times (i.e. surgical start time, surgical end time)  
• Intra -operative estimated blood loss  
• Blood products utilized: cell saver (cc) given, other transfused blo od products (cc)  
• Number of portals  
• Implant tracking Information :  
o Brand and model information of each implanted device  
o Part number, lot number, and UDI of staples, screws, locking caps , and PET 
cord 
o Type and size of screws used  
• The extent of annulectomy (complete or partial) and the presence of pleural closure  
• Whether a thoracoplasty was performed will be noted along with number of ribs and 
whether the pleura was cut or not (internal vs . external thoracoplasty – if used)  
• Posterior based discec tomy  
• Antibiotic use  
• Type and dose of antifibrinolytic  
• Time -exposure of fluoroscopic x-ray during procedure  
21 
 
   [IP_ADDRESS]  Post-surgical  Data (abstracted from medical record)  
• Chest tube drainage on day #1 - #5, and total collected  
• Post-operative day of extubation as well as chest tube removal will be noted  
• Post-operative day the patient was converted entirely to oral pain medication  
• Visual Analogue Scores (measures the intensity of a child’s pain experience) at 
discharge  will be recorded . This is used to  record the amount of back pain a patient is 
experiencing.  
• Day of discharge will be recorded  
• The use of a post -operative brace and the number of months utilized will be recorded  
• Bloodwork levels and results from the hospi[INVESTIGATOR_274366]  
• Complicat ions will be recorded: Complications will be recorded and status will be 
updated until resolved. This data collection methodology will be standardized via the 
complication form in the patient’s study binder . 
• Post-operative  drain: type and drainage amounts daily until d/c of drain  
• Data abstracted from medical records, radiology reports, and surgical logs  
• Post-operative bloodwork  
5.1.3 POD 21 Follow up  
• Medical and radiographic record review : data abstracted from clinical care exam 
(medical records, radiology reports, pulmonology tests)  
• Standing height  
• Weight  
• BMI  
5.1.4 POD -45 and POD -90 Follo w-up 
[IP_ADDRESS]  Post-Operative  Visit  
• Medical and radiographic record review : data abstracted from clinical care exam 
(medical records, radiology reports, pulmonology tests)  
• Standi ng height  
• Weight  
• BMI  
• Trunk flexibility measurements (standardized): Adam’s Forward bending test 
(degrees)  only 
22 
 
   5.1.5 POD -180, POD -365, POD -730 Follow -up 
[IP_ADDRESS]  Extended Follow -up Visit  
• Medical and radiographic record review : data abstracted from clinical care exam 
(medical records, radiology reports, pulmonology tests)  
• Standing height  
• Weight  
• BMI  
• Trunk flexibility measurements (standardized): Adam’s Forward bending test 
(degrees), thoracic and lumbar flexion (cm) , thoracic and lumbar lateral flexion (cm)  
• SRS [ADDRESS_1213197] ionnaire  
• Clinical photographs  
5.1.6 Laboratory Evaluations  
[IP_ADDRESS]  Bloodwork  
Pre-operative b loodwork to be performed:  
• CBC (Complete Blood Count) w ith(out)  Differential  
• CMP (Comprehensive Metabolic Panel) w ith(out)  Albumin  
• PT/INR (Prothrombin Time)  
• PTT Profile (Partial Thromboplastin Profile)  
• Type & Screen  
These tests are  performed pre - and post -operatively for all patients undergoing surgery , at 
clinical discretion . This is done as part of the anesthesia team’s routine evaluation of the 
subject, and for tracking safe recovery. Results of these blood tests will be monitored for any 
abnormal or incidental findings. Abnormal or incidental findings will be documented and 
communicated to the treating physician(s). The treating physician(s) will determine if th ese 
findings would alter the subject’s treatment course in any way.  
[IP_ADDRESS]  Pregnancy Testing : Performed at pre-operative  visit only 
A blood or  urine pregnancy test will be performed for female subjects [ADDRESS_1213198] result. In  this case, the parent(s) will be informed of the positive result. In the 
event of pregnancy, the participant will not receive the study intervention . Participants who 
are found to be pregnant will be advised to contact [CONTACT_869398].  
23 
 
   5.1.7 Other Evaluations, Measures  
Clinical Evaluations/Measurements:  
• Adam’s Forward Bending Test:  Subject stands with their back to the examiner, and 
bends forward at the waist, with knees in extension. The examiner looks at the 
horizontal plane of the spi[INVESTIGATOR_050], a nd measures  the angle created between a rib hump and 
the horizontal plane. This is measured with an inclinometer.  
• Thoracic/Lumbar Flexion  Test: Subject stands with trunk erect while measuring tape 
is placed proximally on the spi[INVESTIGATOR_869286] C7 and dista lly to S1. The subject 
then bends forward at the waist, with knees in extension. Following flexion of the 
vertebrae, using the same bony landmarks, the examiner calculates the difference in 
distance between the starting and ending positions.  
• Thoracic/Lumba r Lateral Flexion Test: Subject stands erect with the feet flat on the 
floor. Place one end of a measuring tape on the tip of the middle finger and the other 
on the floor on a point directly beneath the middle finger. The patient then laterally 
flexes their trunk. The difference  following the lateral flexion motion is measured.  
• Clinical Photographs:  Photographs will be taken of the subject at specified time 
points. The photographs will not include facial features , and include the torso from 
the top of the shoulders to the iliac c rests. The patient should stand in a natural 
standing position for AP, PA, lateral right, and lateral left photos. The subject  will 
perform the Adam’s Forward Bending Test, and a photograph will be taken from the 
view of the examiner (PA). Photos will be t aken without shirt or hospi[INVESTIGATOR_105463]. It is 
permissible for female subjects to wear a top covering that allows for a clear view of 
the spi[INVESTIGATOR_869339]  (bra, sports bra, bathing suit top, or similar) . 
Other Measurements:  
• Sanders Bone Age:  Attached as Supplem ent 1  
• SRS 30 : Attached  as Supplement  [ADDRESS_1213199] safety will be monitored by [CONTACT_869399], and will be recorded on the 
complication form in the patient’s study binder . The evaluation of safety is a primary 
objective of this research study. There will be a clear classification of “device -related” 
adverse events. Device -related adverse events are those events directly related to the 
integrity, safety, or biomechanics of the Anterior Vertebral Tether Device, as described in 
this IDE application, comprised of the staples, screws, locking caps , and PET cord . This can 
include variables like device breakage or device migration. Other adverse events which are 
considered not dev ice-related are those that are related to the act of surgery and medical 
recovery . The type of events will be documented on the CRF.  
5.[ADDRESS_1213200] 
radiographic measurement of curvature of the spi[INVESTIGATOR_050]. This angle will be recorded for the pre -
operative coronal  spi[INVESTIGATOR_844817], as well as all subsequent serial radiographs. The c hange 
24 
 
   in Cobb angle (reduction) will be the primary exploratory therapeutic evaluator of efficacy.  
‘Success’ of the intervention will be defined by a final Cobb angle of less than  or maintained 
at less than 50 degrees, for curves which were less than 50 de grees pre -operatively. For 
curves which were greater than 50 degrees pre -operatively, a Cobb angle which is less than 
or maintained at less than 50 degrees is considered a ‘success’ . 
5.4 Chart Review for Withdrawn Subjects  
Subjects who are withdrawn from the study during the follow -up phase due to AEs/SAEs 
will no longer follow the study visit schedule nor participate in study -specific procedures . 
These subjects have the option to consent and allow for continued monitoring b y medical 
and radiographic record review through the end of the two -year Extended Follow -up Phase. 
Subjects who are withdrawn from the study also have the option to enroll in a separate 
LTFU observational study .  
[ADDRESS_1213201] of the rate of AEs/SAE s in anterior VBT  
surgery.  
6.[ADDRESS_1213202] descriptive 
summaries (e.g. means and standard deviations for continuous variables such as age and 
percentages for categorical variables such as sex). Categorical data analysis methods such as 
chi-square will be used for dichotomous variables and t -test for continuous data  (such as 
differences in C obb angle). Logistic regression analysis will be conducted to analyze various 
factors associated with adv erse events in the anterior tethering surgical procedure.  
6.3.[ADDRESS_1213203] 
undergone anterior VBT  surgery. Variable reporting for adverse event will be dichotomous.  
Descriptive statistics will be used to report number and type of adverse events. Further, chi -
square or Fisher ’s-exact test analysis will be used to identify variables that correlate with 
adverse events following anterior tethering surgery. Further, logistic regression will be 
conducted to clarify which variables are associated with adverse outcomes. Odds ratio along 
with confidence intervals will be reported.  
 
All subjects will begin the safety analysis at Study Day 0 (day of surgery).  Intraoperative 
and post -intervention  medical events or signs and symptoms of the complications arising 
after the start of study intervention  will be captured using list of common events associated 
with anterior VBT surgery. Adverse signs, symptoms, and/or labor atory abnormalities 
already existing prior to the baseline visit will be captured in the medical history assessment.  
The date of onset, severity, and end date (if relevant) will be documented.  
Medical events resulting from any procedure performed in the st udy will be collected as 
adverse events (AEs). The event description, date of onset, end date, severity, and outcome 
will be documented for the study -related AEs. The frequencies of AEs by [CONTACT_24975], body system, 
severity and relationship to study intervention will be summarized. SAEs (if any) will be 
described in detail. A distinction will be made between those AE s/SAEs which are “device -
related”, those which are “not device -related”, and those which are “uncertain to be related”. 
“Device -related” complications  will include any events directly related to the integrity, 
safety, or biomechanics of the Anterior Vertebral Tether Device composed of the 
investigational staples, screws, locking caps , and PET cord . Device -related AE incidence 
will be summarized along wi th the corresponding exact binomial 95% two -sided confidence 
intervals.  
[ADDRESS_1213204] the power calculations described in Section 6.4.  
 
6.4 Sample Size and Power  
The purpose of this study is  to longitudinally follow a cohort of patients treated with a novel 
use of an implant ed device , referred to as the Anterior Vertebral Tether Device, to explore 
safety and feasibility of the implant . Based on device imp lantation  in up to 40 subjects, the 
study will not be sufficiently powered to gain statistical significance. However, this 
preliminary study will allow some insight into the safety of implantation, as measured by [CONTACT_869400], as wel l as feasibility of implantation, as estimated by [CONTACT_869401]. The regulatory 
status of such an implant requires that the Sponsor obtain s an IDE. There is no active 
comparative group in this  limited study. Notably , there is a useful comparator group from 
review of published data (historical controls) and from the data of the Harms Study Group  
(CHOP IRB# 06 -005052) , for which the Sponsor has access.  A comparative analysis will be 
performed com bining data from this clinical trial with IRB# 06 -005052  to evaluate patient 
factors and clinical outcomes depending on the intervention received. Data from this clinical 
trial will not be shared with IRB# [ADDRESS_1213205] thora cic and lumbar measurements for a small sample of 
subjects; for the thoracic measurements, a sample size of [ADDRESS_1213206] >80% power to detect 
a difference in means of 17.9, assuming a standard deviation of differences of 6.6, using a 
paired t -test with a 5 % two -sided significance level. For the lumbar measurements, a sample 
size of [ADDRESS_1213207] >80% power to detect a difference in means of 6.5, assuming a standard 
deviation of differences of 5.38, using a paired t -test with a 5% two -sided significance level . 
Sample size calculations were performed using NQuery software.  
27 
 
   6.5 Interim Analysis  
The study team will perform interim analyses based on the stoppi[INVESTIGATOR_869340] 
6.6 (below). If any of these rules are met, the study will halt enrollment until appropriate 
measures can be put in place to reduce patient risk. All reporting of AE s/SAEs during the 
study will adhere to the guidelines in Section 8 (Safety Management).  
6.6 Stoppi[INVESTIGATOR_869341] t he prevalence of SAEs. There is special 
consideration given to SAE s that are found to be “device -related”, as outlined below.  
6.6.1 Stoppi[INVESTIGATOR_869342]  (surgery)  
• SAE in all of the first 5 patients or  
• SAE in [ADDRESS_1213208] 10 pa tients or  
• SAE in greater than 50% of patients after 15 cases  
 
6.6.2 Stoppi[INVESTIGATOR_869343] -related   
Definition of Terms:  
• Screw failure – screw , locking caps , and/or centering staple have loosened from the 
vertebra AND require re -operation . 
• Tether failure – the tether has broken or lost tension. Diagnosed at any time  point after [ADDRESS_1213209] 
measurement , AND requires re -operation . 
• Implant re -operation - any problem with the implant that requires re -operation including 
re-operation for overcorrection with any of the following: a removal of all or part of the 
implant, loosening of the tension on the implant, or spi[INVESTIGATOR_61680].  
Stoppi[INVESTIGATOR_14123]  
• Screw /locking cap /staple  failure stoppi[INVESTIGATOR_11300]: [ADDRESS_1213210] 10, or in 
greater than 50% of cases  15 and beyond . 
• Tether failure stoppi[INVESTIGATOR_11300]: [ADDRESS_1213211] 10, or greater than 50% of 
cases  15 and beyond . 
• Implant failure re -operation stoppi[INVESTIGATOR_11300]: occurs in [ADDRESS_1213212] 10, or 
greater than 50% of cases 15 and beyond . 
  
28 
 
   7 STUDY DEVICE  
7.1 Description  
The device under investigation is the “Anterior Vertebral Tether Device”, comprised of 
components fro m Globus Medical, Incorporated systems: The Creo ® System  and the 
Transition ™ Stabilization System  or SILC™ Fixation System .  From the Creo ® System  
come the staples, screws , and locking caps  of the investigational device. From the 
Transition ™ Stabilization System  or SILC™ Fixation System  comes the Polyethylene 
Terephthalate  (PET) cord. Th ese four components  are part of a 510K -cleared implant system 
distributed by [CONTACT_260928], Inc . The Creo ® and Transition ™ Globus system s are 
classified as Class II under 21 CFR 888.3070, and SILC™ Fixation System  Globus system is 
classified as Class II under 21 CFR 888.3010. The devices  are manufactured and distributed 
according to manufacturer guidelines and  in compliance with 21 CRF 820 . 
The entire system s are supplied to CHOP as part of routine surgical treatment. The system s 
supplied also includes hydroxyapatite -coated titanium alloy Ti6Al4V (ASTM F136) or alloy 
Ti6Al4Nb (ASTM F1295) pedicle screws, polycarbonate urethane spacers and bumpers, 
titanium alloy spools, end spools, and set screw ends . The rest of the system will b e 
discarded according to the appropriate CHOP OR policies and procedures . 
7.[ADDRESS_1213213] will be 
tracked by [CONTACT_869402]. 
Those parameters include:  
• Manufacturer of device  
• Model name [CONTACT_132166]  
• Device Part Number  
• Device Lot Number  
The device will be received and processed in the usual standard process per hospi[INVESTIGATOR_869344]. The medical record and device form, which will contain the 
parameters stated above, will be the source documents for tracking implanted dev ices. The 
process for device handling and tracking will be conducted in accordance with our study 
device tracking SOP.  
29 
 
   7.4 Indications for Use  
7.4.1 Intent of the Device:  
• The device is intended to normalize the vertebral column of those with pediatric 
idiopathic sc oliosis, by [CONTACT_869403].  
7.4.2 Patient population:  
• Males and females diagnosed with idiopathic scoliosis (all types  - infantile , juvenile, 
adolescent).  
• Spi[INVESTIGATOR_869345].  
• Spondylolysis or Spondylolisthesis is permitted, as long as it is non -operative, the 
patient has not had any previous surgery for this, and no surgery is planned in the 
future.  
7.4.3 Curve types : 
• We will use the Lenke classification system for curve type. The Le nke Classification 
system is a classification for AIS. For those subjects with AIS, the Lenke types 
eligible for inclusion are Lenke types 1, 2, and 3. For those subjects with JIS and IIS 
(idiopathic scoliosis diagnosed before age 10), subjects with curves  patterns that 
match all other criteria to be classified as Lenke types 1, 2, and 3 will be included . 
7.4.4 Levels that will be treated : 
• Thoracic levels T4 -L1 (i.e., most cephalad and caudad levels that may be treated) . 
7.4.5 Growth and skeletal maturity assessment : 
• Chronological age 8 -16 years (inclusive)  
• Sanders bone age less than or equal to  4. 
7.4.6 Range of curve magnitudes that will be treated :  
• Thoracic  curve  greater than or equal to  35 degrees  and less than or equal to  60 
degrees  
• Lumbar curve less than  35 degrees  
  
30 
 
   8 SAFETY MANAGEMENT  
8.1 Clinical Adverse Events  
Clinical adverse events (AEs) will be monitored throughout the study.  
8.2 Adverse Event Reporting  
Unanticipated problems related to the research involving risks to subjects or others that 
occur during the course of thi s study (including SAEs) will be reported to the IRB in 
accordance with CHOP IRB SOP 408: Unanticipated Problems Involving Risks to Subjects. 
AEs that are not serious but that are notable and could involve risks to subjects will be 
summarized in narrative or other format and submitted to the IRB at the time of continuing 
review.  
8.[ADDRESS_1213214] who has received an 
intervention (drug, biologic, or other intervention). The occurr ence does not necessarily 
have to have a causal relationship with the treatment. An AE can therefore be any 
unfavorable or unintended sign (including an abnormal laboratory finding, for example), 
symptom, or disease temporally associated with the use of a medicinal product, whether or 
not considered related to the medicinal product.   
We will use the Clavien -Dindo Classification system [47], as well as the Comprehensive 
Complication Index (based off of the Clavien -Dindo system) [48] to classify and analyze 
patient adverse events.  Grade I and Grade II events will be considered AEs.  (See 
Appendix  1 for classification table)  
8.4 Definition of a Serious Adverse Event (SAE)  
An SAE is any adverse e vent that results in any of th e following outcomes:  
• death,  
• a life -threatening event (at risk of death at the time of the event),  
• requires inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant disability/incapacity, or  
• a congenital anomaly/bi rth defect in the offspring of a subject.  
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse event when, based upon appropriate 
medical judgment, they may jeopardize th e subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  
A distinction should be drawn between serious and severe AEs. A severe AE is a major 
event of its type. A severe AE does not necessarily ne ed to be considered serious. For 
example, nausea which persists for several hours may be considered severe nausea, but 
31 
 
   would not be considered serious . On the other hand, a stroke that results in only a limited 
degree of disability may be considered a mild  stroke, but would be considered serious . 
We will use the Clavien -Dindo Classification system [47], as well as the Comprehensive 
Complication Index (based off of the Clavien -Dindo system) [48] to classify and analyze 
patient adverse events. Grade III (a/b), Grade IV (a/b), and Grade V events will be 
considered SAEs. (See Appendix  1 for classification table)  
8.4.1 Relationship of AE/SAE to study intervention  or device  
The relationship of each Event to the study intervention should be characterized using one of 
the following terms in accordance with CHOP IRB Guidelines: definitely, probably, 
possibly, unlikely , or unrelated . In this case, the “study intervention” in considered to be 
the surgical intervention and implantation of the medical device ( Anterior vertebral body 
tethering surgery under general anesthesia with spi[INVESTIGATOR_869297] ). This includes (but 
is not limited to) induction of anesthesia, incision and surgical approach, de vice 
implantation, and recovery. For each SAE, the PI [INVESTIGATOR_869346] a case -
by-case determination on the relationship of the SAE  to the study procedure , which  
will be documented in the study documents . 
There will be further classification of the Event  as either “ device -related” , “not device -
related” , or “uncertain to be device -related” . Device -related adverse events are those events 
directly related to the integrity, safety, or biomechanics of the implan ted device. This can 
include variables like device breakage or device migration. Other adverse events which are 
considered not device -related are those that are related to the act of the surgery and medical 
recovery (anesthesia, incision and surgical appro ach, post -operative recovery, etc.).  This 
distinction will be indicated in the study documents . For each E vent, the PI [INVESTIGATOR_869347] a case -by-case determination on whether the E vent is “device 
related” , “not device related”,  or “uncertain” . An event  which is classified as “device 
related” will be considered an Adverse Device Effect . Adverse device effects have 
special reporting guidelines, as outlined below.  
8.5 Recording  plan for AE s/SAEs  
Surgery and Post -operative Phase (Day 0 – POD 90) : 
For these phases, all AEs (including SAEs ) will be noted in the s tudy records and reported 
per IRB and FDA requirements outlined below. The subjects will be encouraged to contact 
[CONTACT_869404],  and the medical record  will be monitored by [CONTACT_869405].  
Extended Follow -up Phase (POD 91 -POD 730) : 
For this phase,  all SAEs will be recorded  (regardless of cause). Only  AEs which are deemed 
“device related” will be recorded on study documents  and reported per IRB and FDA 
require ments outlined below. The subjects will still be encouraged to contact [CONTACT_869406],  and the medical record  will be monitored by [CONTACT_869407] -related AEs.  
Long -term Follow -Up (POD 730 through approximately two years after skeletal maturity ): 
32 
 
   An observational study involving c hart review of medical charts from CHOP and external 
sources as needed will be undertaken for long -term follow -up. All SAEs identified from the 
medical records that are considered device related , up to two years after skeletal maturity, 
will be reported  in accordance with  FDA requirements . This will be performed under a 
separate research protocol.  
Only t he AE s/SAEs indicated above will be recorded in a patient -specific study binder, kept 
in the secure orthopedics research office. The binder will contain a full description of the 
event, including the nature, date and time of onset, determination of non -serious v ersus 
serious, intensity (mild, moderate, severe), duration, causality, and outcome of the event. 
Hard copi[INVESTIGATOR_869348] (medical record notes) describing the event and any 
associated treatment will be printed and kept in the patient -specific  study binder.  A 
redundant copy of adverse events will be kept in the study REDCap database and will be 
maintained by [CONTACT_869408] -specific study binder. The study 
binder will serve as the official record of all Events.  
8.6 IRB/IE C Notification of SAEs and Other Unanticipated Problems  
The Investigator will promptly notify the IRB of all on -site unanticipated, serious adverse 
events that are related to the research activity. Other unanticipated problems related to the 
research invol ving risk to subjects or others will also be reported promptly. Written reports 
will be filed using the eIRB system and in accordance with the timeline below. External 
SAEs that are both unexpected and related to the study intervention will be reported 
promptly after the investigator receives the report. External events that do not change the 
risk to subjects or result in a change to the research protocol will be reported to the IRB 
following IRB recommendations.  
REPORTING REQUIREMENTS TO THE IRB  
Type of Unanticipated 
Problem  Initial Notification  
(Phone, Email, Fax)  Written Report  
Internal (on -site) SAEs  
Death or Life 
Threatening  24 hours  Within 2 calendar days  
Internal (on -site) SAEs  
All other SAEs  7 days  Within 7 business days  
Unanticipated Problems 
Related to Research  7 days  Within 7 business days  
All other AEs  N/A Brief Summary of 
important AEs may be 
reported at time of 
continuing review  
33 
 
   8.6.1 Follow -up report  
If an SAE has not resolved at the time of the initial report and new information arises that 
changes the investigator’s assessment of the event, a follow -up report including all relevant 
new or reassessed information (e.g., concomitant medication, medical history) should be 
submitted to the IRB. The investigator is resp onsible for ensuring that all SAE are followed 
until either resolved or stable.  
8.7 Investigator Reporting Requirements to IRB and FDA  
INVESTIGATOR REPORTING TO THE FDA/DEVICE MANUFACTURER  
Type of Report  Description of Report  Submit to:  Timeline  
Unanticipated Adverse 
Device Effects  Report of any 
unanticipated adverse 
device effect  IRB and FDA  Within [ADDRESS_1213215]’s life  or 
physical well -being (i.e. 
during an emergency)  IRB, Sponsor  Within [ADDRESS_1213216]  
34 
 
   Voluntary Reports  At discretion of 
investigator. Voluntary 
adverse event reporting 
is done through Form 
3500A.  IRB, FDA  As deemed by [CONTACT_1697]  
8.8 Sponsor Reporting Requirements  to FDA and IRB 
SPONSOR REPORTING TO THE IRB/ FDA  
Type of Report  Description of 
Report  Submit to:  Timeline  
Unanticipated Adverse 
Device Effects  Report of any 
unanticipated 
adverse device 
effect  FDA and 
reviewing IRB(s)  Within [ADDRESS_1213217] receives 
notice. May submit further 
reports at FDA requests  
Withdrawal of IRB 
approval  If IRB withdraws 
approval of 
investigation or 
part of the 
investigation  FDA and 
reviewing IRB (s) 
and participating 
investigators  Within 5 working days  of 
receipt of notice  
Withdrawal of FDA 
approval  If FDA withdraws 
approval  Reviewing IRB(s) 
and participating 
investigators  Within [ADDRESS_1213218] of 
names and 
addresses of all 
participating 
investigators  FDA  12 month intervals  
Progress Report  FDA Form 3419  FDA and 
reviewing IRB(s)  Regular intervals, no less 
than every [ADDRESS_1213219] 24 months of the study.  
Recall and Device 
Disposition  If Sponsor 
requests return, 
repair, or disposal 
of device, and 
why FDA and 
reviewing IRB(s)  Within [ADDRESS_1213220] is made  
35 
 
   Final Report  Complete and 
final investigative 
report  FDA and 
reviewing IRB(s)  1. Notify FDA within [ADDRESS_1213221]  FDA and 
reviewing IRB(s)  Per request  
8.[ADDRESS_1213222].  
36 
 
   9 STUDY ADMINISTR ATION  
9.1 Data Collection and Management  
1. Confidentiality:  
A master list will be maintained separately from the coded data collection sheet and 
will contain the subject ID number, name, MRN, date of birth , dates of service , 
approximate date at which the subject  will need to reconsent upon turning 18, and 
whether or not the subject has consented for the use of their data for future research 
studies . The list will be password -protected so that only the study staff will have 
access. Data will be collected on each s ubject using the subject’s Study ID number. 
Data , including PHI,  will be managed and stored using the research -focused 
electronic data capture system REDCap, under an agreement with the software’s 
development consortium, led by [CONTACT_50222]. REDCa p supports two 
secure, web -based applications designed exclusively to support data capture for 
research studies. REDCap is a PHP web application served by [CONTACT_630644] 
a 128 -bit SSL connection using a signed certificate. The application relies on a 
study-specific data dictionary defined in an iterative self -documenting process that 
will be conducted by [CONTACT_59881]. The data dictionary is the 
foundation for custom case report form design and validated coding of variables. 
Authentic ation of research staff will be performed via LDAP using CHOP’s 
enterprise Active Directory service. The application generates a complete audit trail 
of user activity, provides reporting, and has an automated export mechanism to 
common statistical packages  (SAS, SPSS, Stata, R/S -Plus).  
A patient -specific study binder will be kept for each enrolled patient. The study 
binder will contain adverse event information, signed consent forms , paper forms 
collected during testing , as well as all  other  relevant docum entation. These  will be 
stored in a locked research office.  
2. Data Sharing:  
Coded data will be transferred from CHOP to [CONTACT_869426] a t Drexel 
University for research collaboration and data analysis via CD/DVD, secure 
electronic file transfer, and/or on protected Excel spreadsheets sent by [CONTACT_869409][INVESTIGATOR_851285]. All data transferred will be labeled with the subject’s study ID and 
will n ot include PHI. [CONTACT_187292] at Drexel University will not have access 
to the master list, therefore this data will not be identifiable to them.  
A Limited Data Set , including images, will be transferred from CHOP to Globus  
Medical, Inc. as part of a  license agreement executed between the two parties  for use 
in the manufacturer’s humanitarian device exemption (HDE) submission . Images 
will be limited to images of subjects’ torsos and will not include video recordings, 
subject faces, or identifiable fea tures. Data will be sent by [CONTACT_869410] . Hardcopy documents will be redacted 
to remove identifiers and be transferred via courier or in -person from study team 
member to an authorized representative of Globus Medical, Inc. Data transferred will 
[ADDRESS_1213223] to link data back to subjects.  
3. Security:  
The master sheet will be a password protected Excel file kept in the secure 
orthopedic research drive at CHOP . The REDCap MySQL database is replicated in 
real time to a completely redundant instance of MySQL. The redundant instance is 
available for restora tion of the primary database or for manual failover in the case of 
primary database failure. Time -stamped backup files are made from the replicated 
database daily by [CONTACT_869411]. Backup files are encryp ted and transferred to a secure file server accessible 
only to designated personnel. A rolling seven -day window of backup files is 
maintained in an immediately available online state, with a larger window 
maintained in a compressed file archive available a t a reduced speed of access. Daily 
destructive database backup files are stored on the database server and are deleted 
only after successful backup of the entire database to file. In the event of data error, 
loss or corruption, research personnel will work  with CHOP Research Information 
Systems to determine the most appropriate recovery strategy. Data and backups are 
stored in the CHOP Research Information Systems Storage Area Network (SAN). 
Access to the SAN directories where data are stored will be limite d to Research 
Information Systems personnel, with authentication performed using CHOP’s 
enterprise Active Directory service. The data from the application will be compi[INVESTIGATOR_869349] a secured survey web platform that is encrypted using AES 256 bit encryption. 
The data collected on paper forms during testing will be secured in the patient -
specific study binders in a locked research office.  
 
4. Anonymization, de -identification or destruction:  
Data will be collected on each subject using the subject’s study ID number. Study 
personnel will  store a list connecting the subject’s PHI to study ID. All PHI collected 
from this study will be destroyed two years after the last  marketing application has 
been approved or two years after all research of the study has been completed,  and as 
approved by [CONTACT_1034].  
9.[ADDRESS_1213224] obtaining IRB approval.  
9.3 Regulatory and Ethical Considerations  
9.3.1 Data and Safety Monitoring Plan  
The PI [INVESTIGATOR_869350] d ata and safety throughout the duration of the study and will report any 
adverse events in accordance with IRB policies.  The PI, Safety Monitor, and study team will 
38 
 
   perform interim safety analyses as outlined in Section 6.6. Safety monitoring will be handled 
internally by [CONTACT_869412] (ORC). 
We will also submit reports to the FDA, device manufacturer, or both as per medical device 
reporting requirements specified in 21CFR803.  
9.3.2 Risk Assessment  
This section outlines risks associated with the study procedures.  
[IP_ADDRESS]  Surgical Procedure: Anterior -approach thoracoscopic vertebral body tethering 
(greater than minimal risk)  
• Radiation Exposure (Fl uoroscopy and X -ray):  This study involves exposure to 
radiation from  intraoperative fluoroscopy and x -rays. The patient will receive a 
radiation dose, which is necessary for completion of the operation. Radiation can 
increase the risk of cancer after many years but at a dose much higher than the 
patient will receive. Becau se of the low dose of radiation, it is very likely that the 
patient will see no ill effects.  
Radiation exposure will be tracked during the surgery. This will be recorded as 
fluoroscopic exposure time recorded in minutes. The widely -accepted ALARA (as 
low as reasonably acceptable) principle will be used to ensure surgeons are imparting 
the lowest radiographic dose possible onto the patient [49]. 
• Neurological Injury : There is risk for neurological injury  in all surgeries involving 
spi[INVESTIGATOR_869351]. Intra -operative neuromonitoring (IONM) 
will be used by [CONTACT_869413]. There are no known 
adverse neuromonitoring events occurring wi th this surgery in the literature [21]. 
• Bleeding : Bleeding is a risk for any surgical procedure. Every reasonable effort will 
be made by [CONTACT_869414]. Estimated b lood loss during 
surgery (EBL) will be recorded on CRFs.  
• Infection : Infection is a risk for any surgical pr ocedure or hospi[INVESTIGATOR_4408]. All CHOP 
SOPs regarding sterile procedures and institutional policies on infection prevention 
will be followed to prevent infection. The patient will be placed on CHOP 
Orthopedics SOP for pre - and post -operative antibiotic regimen  for spi[INVESTIGATOR_481749].  
• Pain: Pain is a risk for a patient during post -operative recovery. CHOP orthopedics 
pain team will be consulted for pain management in the time following the surgery, 
to best manage post -operative pain.  
• Pneumothorax : After surg ery, the patient will be monitored for pneumothorax by 
[CONTACT_869415][INVESTIGATOR_33717]. If a pneumothorax is found, it may cause elongation of the 
patient’s hospi[INVESTIGATOR_4408], or require medical/surgical intervention.  
• Bronchopulmonary plug : After surgery, the patient  will be monitored for presence of 
a bronchopulmonary plug by [CONTACT_869415][INVESTIGATOR_33717]. If a bronchopulmonary plug is 
found, it may cause elongation of the patient’s hospi[INVESTIGATOR_4408], or require a 
medical/surgical intervention.  
• Implant Failure : We will dilige ntly monitor the patient  both during and after surgery  
for signs of implant failure. Some types of implant failure could be:  
39 
 
   o Screw failure – screw and/or centering staple have loosened from the vertebra 
AND require re -operation . 
o Tether failure – the tether  has broken or lost tension. Diagnosed at any time 
point after [ADDRESS_1213225] measurement , AND requires re -operation . 
o Implant re -operation - any problem with the implant that requires re -
operation including re -operation for overcorrection with any of the following: 
a removal of all or part of the implant, loosening of the tension on the 
implant, or spi[INVESTIGATOR_61680].  
• Overcorrection : It is possible for the device to impart more than the intended 
correction to the spi[INVESTIGATOR_269688]. This event will be monitored by [CONTACT_869416] -
up th roughout the study, and may require medical or surgical intervention.  
It should be noted that the above risks are the same risks that are present for standard -of-
care surgery for spi[INVESTIGATOR_61678]. All appropriate clinical care procedures and pathways 
followe d for standard -of-care spi[INVESTIGATOR_869352].  
[IP_ADDRESS]  No greater than minimal risk study procedures:  
• Review of medical records : There is a risk of breach of confidentiality and privacy as 
a result of medical record review. This risk is mi nimized as detailed in Section 9 . 
• Administration of questionnaires : The questionnaires have the potential to make 
subjects feel uncomfortable. Sub jects will be allowed to skip questions which they 
are not comfortable answering without compromising their participation in the study.  
• Study -specific physical exam:  The study physical exam uses non -invasive 
measurement techniques commonly employed in clin ical practice.  
• Clinical photographs:  There is a risk of breach of confidentiality in subject 
photographs. This risk is minimized by [CONTACT_869417], and by 
[CONTACT_869418] 9.  
[IP_ADDRESS]  Risks associated with live case demons tration:  
• Extended anesthesia exposure:  Time under anesthesia may be extended minimally , at 
most a few minutes,  due for example to additional setup procedures, however, this 
preparation will be done by [CONTACT_869419].  
• Infection risk:  There may be added risk of infection with more personnel a nd 
additional equipment in the room. However, any additional staff that may be in the 
operating room will be educated on safe clinical practices when entering and will 
remain outside of the sterile field during observation. Only the surgeon and other 
relev ant clinicians will be allowed in the sterile field. Any additional equipment used 
will be covered with sterile cloth and utilized only as necessary during the procedure.  
• Surgeon distraction: This risk will be addressed by [CONTACT_7661] a separate surgeon 
handlin g commentary of the procedure, allowing the performing investigator and 
surgical team to continue the surgery as would normally be conducted without 
distraction.  
40 
 
   • Breach of confidentiality:  There is a risk of loss of privacy if identifying information 
is inadvertently disclosed during the surgery. Staff will be aware to not disclose 
identifying information during the surgical case, unless necessary. If identifying 
information is disclosed, the videotaped record will be edited to remove those 
frames. No recor ding system can completely guard against risks such as a breach 
caused by [CONTACT_869420], inadvertent disclosure of information, or the 
failures or limitations of equipment used to transmit live or recorded data.  
The investigators believe these additional risks associated with the live case demonstration 
are minimal.  
 
9.3.[ADDRESS_1213226] shown that there 
is a lower surgical risk in anterior -approach spi[INVESTIGATOR_869353]  [19]. 
Vertebral body tethering has the theoretical potential for improvement over the outcomes of 
posterior spi[INVESTIGATOR_61680]. In particular, the durability of the posterior spi[INVESTIGATOR_869354]. Posterior pedicle screw constructs came int o popularity in the early 2000’s 
and new [ADDRESS_1213227] 10% of AIS fusions require revisio n surgery by [ADDRESS_1213228]-op and that this trend is 
progressive  [28]. Other authors have also reported on high long term re-operation rates 
following AIS fusion surgery ranging from 4.6% to 19%  [29-31]. One theory is that a fusion 
imparts increased stress on unfused segments below a fusion. Marks et al. have shown that 
patients will retain total lumbar motion after a posterio r spi[INVESTIGATOR_869355]  [32]. The authors postulate that increased motion may lead to 
degeneration of discs and facet joints. These findings of supraphysiologic motion below a 
posterior spi[INVESTIGATOR_869356]. Green et al. have studied the health of intervertebral discs below a spi[INVESTIGATOR_869357] 11.8 years following posterior spi[INVESTIGATOR_61680]  [33]. The authors found that disc 
degeneration was occurring in 85% of patients and the discs when graded by [CONTACT_869421], an objective validated measure of disc degeneration, demonstrated an average 
decrea se from 1.[ADDRESS_1213229]-spi[INVESTIGATOR_869328]  [34]. Lastly, posterior spi[INVESTIGATOR_869329], the population in whom we are proposing 
vertebral tethering, are at increased risk of complications and re -operation. Sponseller  et al. 
reported that patients with open triradiate cartilages undergoing spi[INVESTIGATOR_869358] (development of deformity below a fusion) and the response 
of the un -instrumented lumbar curve is less predictable  [35]. 
41 
 
   The basic science literature suggests that this study intervention has the potential benefit to 
preserve motion of the spi[INVESTIGATOR_869359] -term follow -up, compared  to traditional PSF [37-39]. 
Indirectly, participation in this tria l will benefit the scientific community as a whole. Results 
from this trial will guide standard practice in a novel approach to spi[INVESTIGATOR_869360].  
9.3.[ADDRESS_1213230] (and indirect) benefits will be p resented to the patients by [CONTACT_869422] . The Investigators believe that benefits outweigh the risks based 
on all current knowledge and literature on the subject.  
9.4 Recruitment Strategy  
Subjects will be recruited by [CONTACT_869423]. 
Potential subjects who may satisfy the inclusion/exclusion criteria will be identified by [CONTACT_869424], and will contact a study team member. The study team membe r will use the 
“Screening CRF” to assess preliminarily whether a potential subject may meet 
inclusion/exclusion  criteria. Then, the study team member will confer with the PI [INVESTIGATOR_1238]/or 
Investigators to determine whether the patient should be approached to offe r the clinical trial 
to the subject and family. Potentially eligible patients will then be approached for informed 
consent/assent.  Before being presented with the clinical trial, patients that qualify in 
accordance with the FDA -approved labeling of the HUD , The Tether  – Vertebral Body 
Tethering System , will be offered the approved device first.  
In addition, the study recruitment material will be posted on CHOP Orthopaedics 
department website as an additional source for recruiting potential subjects. A print ed packet 
hand -out will also be available to interested families. These recruitment materials  will 
include information regarding the surgical procedures, risks and follow -up care.  
9.5 Informed Consent/Assent and HIPAA Authorization  
After the subject has made t he decision to have surgery and discussed this decision with 
their doctor , potential subjects who may satisfy the inclusion/exclusion criteria will be 
identified by [CONTACT_869425], who will contact a study team member. Eligible patients will 
then under go consent/assent during their orthopedic visit. This will take place in a private 
exam room in the clinic. The study will be explained to the patients/families and they can 
decide whether to participate in the study. Subjects and their families will be gi ven the 
opportunity to ask questions and may take as long as they need to make a decision.  
For subjects that are withdrawn from the study due to AEs/SAEs, as determined by [CONTACT_1275], they will undergo consent/assent during their orthopedic visit to decide whether 
they agree to review of medical and radiographic records following the occurrenc e of the 
AE/SAE up to two years post -operative ly.  
9.6 Payment to Subjects/Families  
No payment will be given to subjects or families.  
[ADDRESS_1213231] enrollment, data collection , and analysis, a manuscript 
will be prepared and submitted to an appropriate journal in order to contribute to the 
literature on this topic.   
43 
 
   11 REFERENCES  
1. Vialle, R., C. Thevenin -Lemoine,  and P. Mary, Neuromuscular scoliosis.  Orthop 
Traumatol Surg Res, 2013. 99([ADDRESS_1213232]): p. S124 -39. 
2. Levy, B.J., et al., Complications associated with surgical repair of syndromic 
scoliosis.  Scoliosis, 2015. 10: p. 14.  
3. Lenke, L.G., et al., Adolescent idi opathic scoliosis: a new classification to determine 
extent of spi[INVESTIGATOR_495391].  J Bone Joint Surg Am, 2001. 83-A(8): p. 1169 -81. 
4. Gorman, K.F., C. Julien, and A. Moreau, The genetic epi[INVESTIGATOR_869361].  Eur Spi[INVESTIGATOR_050] J, 2012. 21(10): p. 1 905-19. 
5. Miller, N.H., Cause and natural history of adolescent idiopathic scoliosis.  Orthop 
Clin North Am, 1999. 30(3): p. 343 -52, vii.  
6. Horne, J.P., R. Flannery, and S. Usman, Adolescent idiopathic scoliosis: diagnosis 
and management.  Am Fam Physician , 2014. 89(3): p. 193 -8. 
7. Blount, W.P. and F. Zeier, Control of bone length.  J Am Med Assoc, 1952. 148(6): 
p. 451 -7. 
8. Stokes, I.A., et al., Mechanical modulation of vertebral body growth. Implications 
for scoliosis progression.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 1 996. 21(10): p. 1162 -7. 
9. By[CONTACT_423798] -Austrow, D.I., et al., Spi[INVESTIGATOR_869362].  J Bone Joint Surg Am, 2009. 
91(3): p. [ADDRESS_1213233] Times on Scoliosis Surgery: The 
Surgeion's Perspective.  Spi[INVESTIGATOR_050], 2015.  
11. Miyanji, F., et al., Is Larger  Scoliosis Curve Magnitude Associated with Increased 
Perioperative Health -Care Resource Utilization?: A Multicenter Analysis of 325 
Adolescent Idiopa thic Scoliosis Curves.  J Bone Joint Surg Am, 2012.  
12. Katz, D.E., et al., Brace wear control of curve progression in adolescent idiopathic 
scoliosis.  J Bone Joint Surg Am, 2010. 92(6): p. 1343 -52. 
13. Weinstein, S.L., et al., Effects of bracing in adolesc ents with idiopathic scoliosis.  N 
Engl J Med, 2013. 369(16): p. [ADDRESS_1213234] of Compliance Counseling on Brace Use and Success in 
Patients with Adolescent Idiopathic Scoliosis.  J Bone Joint Surg Am, 2016. 98(1): p. 
9-14. 
15. Karol, L.A., et al., The Effect of the Risser Stage on Bracing Outcome in Adolescent 
Idiopathic Scoliosis.  J Bone Joint Surg Am, 2016. 98(15): p. 1253 -9. 
16. Jarvis, J., S. Garbedian, and G. Swamy, Juvenile idiopathic scoliosis: the 
effectiveness of part -time bracing.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2008. 33(10): p. 1074 -8. 
17. Charles, Y.P., et al., Progression risk of idiopathic juvenile scoliosis during pubertal 
growth.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2006. 31(17): p. 1933 -42. 
18. Yrjonen, T., et al., Results of brace treatment of adolescent idiopathic scoliosis in 
boys compared with girls: a retrospective study of 102 patients treated with the 
[LOCATION_011] brace.  Eur Spi[INVESTIGATOR_050] J, 2007. 16(3): p. 393 -7. 
44 
 
   19. Misterska, E., M. Glowacki,  and J. Latuszewska, Female patients' and parents' 
assessment of deformity - and brace -related stress in the conservative treatment of 
adolescent idiopathic scoliosis.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2012. 37(14): p. 1218 -23. 
20. Newton, P.O., et al., Surgical treat ment of Lenke 1 main thoracic idiopathic 
scoliosis: results of a prospective, multicenter study.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2013. 
38(4): p. 328 -38. 
21. Newton, P.O., et al., Use of video -assisted thoracoscopic surgery to reduce 
perioperative morbidity in scoli osis surgery.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2003. 28(20): p. 
S249 -54. 
22. Newton, P.O., et al., The success of thoracoscopic anterior fusion in a consecutive 
series of 112 pediatric spi[INVESTIGATOR_869363].  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2005. 30(4): p. 
392-8. 
23. Samdani , A.F., et al., Anterior vertebral body tethering for idiopathic scoliosis: two -
year results.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2014. 39(20): p. 1688 -93. 
24. Samdani, A.F., et al., Anterior vertebral body tethering for immature adolescent 
idiopathic scoliosis: one -year results on the first 32 patients.  Eur Spi[INVESTIGATOR_050] J, 2015. 
24(7): p. 1533 -9. 
25. Lonner, B.S., et al., Video -assisted thoracoscopic spi[INVESTIGATOR_869364].  J Bone Joint Surg Am, 2009. 91(2): p. 398 -408. 
26. Newton, P.O., et al., Surgical Treatment of Main Thoracic Scoliosis with 
Thoracoscopic Anterior Instrumentation.  Surgical Technique, 2009. 91(Supplement 
2): p. 233 -248. 
27. Kishan, S., et al., Thoracoscopic scoliosis surgery affects pulmonary function less 
than thoracotomy at 2 years postsurgery.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2007. 32(4): p. 453 -
8. 
28. Newton, P.O., et al., Predictors of change in postoperative pulmonary function in 
adolescent idiopathic scoliosis: a prospective study of 254 patients.  Spi[INVESTIGATOR_050] (Phila Pa 
1976), 2007. 32(17): p. 1875 -82. 
29. Faro, F.D., et al., Perioperative changes in pulmonary function after anterior 
scoliosis instrumentation: thoracoscopic versus open a pproaches.  Spi[INVESTIGATOR_050] (Phila Pa 
1976), 2005. 30(9): p. [ADDRESS_1213235] defining late operative site pain of unknown cause.  
Spi[INVESTIGATOR_050] (Phila Pa 1976), 2000. 25(4): p. 463 -8. 
32. Kuklo, T.R., et al., Surgical revision rates of hooks versus hybrid versus screws 
versus combined anteroposterior spi[INVESTIGATOR_869365].  
Spi[INVESTIGATOR_050] (Phila Pa 1976), 2007. 32(20): p. 2258 -64. 
33. Ramo, B.A. and B.S. Richards, Repeat surgical interventions following "definitive" 
instrumentation and fusion for idiopathic scoliosis: five -year update on a previously 
published  cohort.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2012. 37(14): p. 1211 -7. 
45 
 
   34. Marks, M., et al., Postoperative segmental motion of the unfused spi[INVESTIGATOR_869366] 100 patients with adolescent idiopathic scoliosis.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 
2012. 37(10): p. 826 -32. 
35. Green, D.W., et al., Long -term magnetic resonance imaging follow -up demonstrates 
minimal transitional level lumbar disc degeneration after posterior spi[INVESTIGATOR_869367].  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2011. 36(23): p. 1948 -54. 
36. Upasani, V.V., et al., Adolescent idiopathic scoliosis patients report increased pain 
at five years compared with two years after surgical treatment.  Spi[INVESTIGATOR_050] (Phila Pa 
1976), 2008. 33(10): p. 1107 -12. 
37. Sponseller, P.D., et al., Differences in curve behavio r after fusion in adolescent 
idiopathic scoliosis patients with open triradiate cartilages.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 
2009. 34(8): p. 827 -31. 
38. Lonner, B.S., et al., Evolution of Surgery for Adolescent Idiopathic Scoliosis Over 20 
Years: Have Outcomes Impro ved? The Spi[INVESTIGATOR_83217]. 16(10): p. S242.  
39. Newton, P.O., et al., Effects of intraoperative tensioning of an anterolateral spi[INVESTIGATOR_869368] a porcine model.  Spi[INVESTIGATOR_050], 2011. 36(2): p. 109 -
17. 
40. Newton, P.O., et al., Multilevel sp inal growth modulation with an anterolateral 
flexible tether in an immature bovine model.  Spi[INVESTIGATOR_050] (Phila Pa 1976), 2005. 30(23): p. 
2608 -13. 
41. Newton, P.O., et al., Asymmetrical flexible tethering of spi[INVESTIGATOR_869369].  Spi[INVESTIGATOR_050], 2002. 27(7): p. 689 -93. 
42. Newton, P.O., et al., Spi[INVESTIGATOR_869370] a tether in an immature 
porcine model.  J Bone Joint Surg Am, 2008. 90(12): p. 2695 -706. 
43. Danielsson, A.J., et al., Health -related quality of life in untreated  versus brace -
treated patients with adolescent idiopathic scoliosis: a long -term follow -up. Spi[INVESTIGATOR_050] 
(Phila Pa 1976), 2010. 35(2): p. 199 -205. 
44. Weinstein, S.L. and I.V. Ponseti, Curve progression in idiopathic scoliosis.  J Bone 
Joint Surg Am, 1983. 65(4): p. 447 -55. 
45. Weinstein, S.L., D.C. Zavala, and I.V. Ponseti, Idiopathic scoliosis: long -term 
follow -up and prognosis in untreated patients.  J Bone Joint Surg Am, 1981. 63(5): p. 
702-12. 
46. Nachemson, A., A long term follow -up study of non -treated scolio sis. Acta Orthop 
Scand, 1968. 39(4): p. 466 -76. 
47. DiMeglio, A., F. Canavese, and Y.P. Charles, Growth and adolescent idiopathic 
scoliosis: when and how much?  J Pediatr Orthop, 2011. 31([ADDRESS_1213236]): p. S28 -36. 
48. Sanders, J.O., et al., Predicting scoliosis progression from skeletal maturity: a 
simplified classification during adolescence.  J Bone Joint Surg Am, 2008. 90(3): p. 
540-53. 
49. Dindo, D., N. Demartines, and P.A. Clavien, Classification of surgical 
complications: a new proposal with evaluation in a cohort of 6336 patients and 
results of a survey.  Ann Surg, 2004. 240(2): p. 205 -13. 
50. Slankamenac, K., et al., The comprehensive complication index: a novel continuous 
scale to measure surgical morbidity.  Ann Surg, 2013. 258(1): p. 1 -7. 
46 
 
   51. Strauss, K.J. and S.C. Kaste, ALARA in pediatric interventional and fluoroscopic 
imaging: striving to keep radiation doses as low as possible during fluoroscopy of 
pediatric patients --a white paper executive summary.  J Am Coll Radiol, 2006. 3(9): 
p. 686 -8. 
  
47 
 
   12 APPENDIX  
12.1 Appendix 1: Clavien -Dindo complications classification system (from Dindo, 
et al. ) 
 
